https://trial.medpath.com/news/e3132ac0721879d9/boehringer-s-ofev-nears-eu-approval-for-systemic-sclerosis-related-lung-disease 2025-02-11T20:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/a34454727a28646c/novel-minimally-invasive-triple-t-therapy-shows-promise-in-treating-primary-aldosteronism 2025-02-11T20:01:30+00:00 hourly 0.9 https://trial.medpath.com/news/d9993e3935d8c740/novel-anti-platelet-drug-at-10-shows-promise-in-overcoming-clopidogrel-resistance 2025-02-11T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/63280cb5537dd59e/cosmos-health-s-novel-weight-management-device-ccx0722-enters-final-development-stage-targeting-2026-launch 2025-02-11T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/176ae33dc6cc7c70/octavian-therapeutics-emerges-with-new-brand-and-ps10m-fundraising-plan-for-neuropathic-pain-drug-development 2025-02-11T19:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/bd950ce98b3bc0dc/pikaso-trial-investigates-metformin-for-preventing-post-acl-surgery-osteoarthritis 2025-02-11T19:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/9f8d22c16a36ca42/ifb-088-shows-promise-in-phase-2-trial-for-bulbar-onset-als-demonstrating-slower-disease-progression 2025-02-11T19:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/a50f6aaffb15ef67/inventiva-restructures-halves-workforce-to-focus-on-late-stage-mash-drug-lanifibranor 2025-02-11T19:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/d51092669e63b0f5/vancomycin-shows-promise-in-treating-psc-associated-inflammatory-bowel-disease 2025-02-11T19:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/dd016cfce5f5394e/goldman-sachs-downgrades-dynavax-on-competitive-pressures-in-shingles-and-hepatitis-b-markets 2025-02-11T19:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/5c2b84a0ab8f62e4/abviro-initiates-nih-backed-human-challenge-trial-for-novel-dengue-therapy 2025-02-11T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/a7e8a301adc1890a/microbot-medical-secures-13m-funding-to-advance-revolutionary-endovascular-robotic-system 2025-02-11T18:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/0fa13c588465f01b/allostem-cell-therapy-shows-80-efficacy-in-one-year-type-2-diabetes-trial 2025-02-11T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/6b5ab1a2d23ab459/theraclion-s-sonovein-r-speedpulse-innovation-promises-faster-varicose-vein-treatment 2025-02-11T17:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/41c9419d5619763a/pfizer-s-mevrometostat-shows-promising-results-in-phase-i-prostate-cancer-trial 2025-02-11T17:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/b48df3663ea0c47d/cereno-scientific-s-cs014-successfully-completes-first-phase-of-safety-trial-for-pulmonary-fibrosis-treatment 2025-02-11T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/378376cab7897e5d/kiora-pharmaceuticals-advances-kio-104-to-phase-2-trial-for-retinal-macular-edema-treatment 2025-02-11T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/1f464114a0988ed8/combination-chemo-immunotherapy-shows-promise-in-bladder-preserving-treatment-for-muscle-invasive-cancer 2025-02-11T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/news/9f14c93ed0e6c29e/yaqrit-advances-l-ornithine-phenylacetate-to-phase-3-for-acute-hepatic-encephalopathy-treatment 2025-02-11T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/8b2d807335ad8c0a/eu-launches-multi-country-clinical-trial-assessment-pilot-to-streamline-approval-process 2025-02-11T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/7bfc38a83ba2c187/novartis-acquires-anthos-therapeutics-for-925m-aims-to-advance-novel-blood-thinner-abelacimab 2025-02-11T16:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/7d95fcf321e5730e/usaid-funding-freeze-disrupts-global-clinical-trials-and-health-programs 2025-02-11T16:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/47ea03e7f37e072b/fortrea-selected-to-lead-fda-clinical-trials-for-ai-powered-diabetic-retinopathy-detection-platform 2025-02-11T16:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/c85e44c9e7e9faa8/novel-hif-2a-inhibitor-casdatifan-shows-promise-in-advanced-kidney-cancer-phase-1-trial 2025-02-11T16:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/1f2e282e4654c809/lineage-cell-therapeutics-launches-dosed-study-for-novel-spinal-cord-injury-cell-therapy 2025-02-11T16:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/dc50b60ab6148450/enhanced-navigation-program-significantly-improves-timing-of-post-surgery-radiation-in-head-and-neck-cancer 2025-02-11T15:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/85ec5a8baecda8f4/ultrasound-activated-nanoparticles-enable-precise-drug-delivery-to-deep-brain-regions-in-primates 2025-02-11T14:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/f5093e60a7b2c912/novartis-to-acquire-anthos-therapeutics-for-925m-advancing-novel-stroke-prevention-drug-abelacimab 2025-02-11T14:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/c71b089bafda0717/third-harmonic-bio-s-thb335-shows-promising-phase-1-results-for-chronic-urticaria-treatment 2025-02-11T14:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/6100111b82b19e9e/fda-grants-priority-review-to-troriluzole-for-spinocerebellar-ataxia-treatment 2025-02-11T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/699b3ea9ab51d50e/zeo-scientifix-advances-regenerative-medicine-portfolio-with-successful-phase-i-completion-of-zofintm 2025-02-11T13:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/c55f2bcd1901969e/study-reveals-healthcare-access-barriers-and-cardiovascular-risk-profiles-in-ibd-treatment-options 2025-02-11T12:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/114f2c5357ffc318/clinical-trial-success-industry-expert-outlines-key-strategies-for-better-site-engagement 2025-02-11T12:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/2598ad13b3aaac43/trump-s-tariffs-set-to-reshape-us-clinical-trial-landscape-and-drug-manufacturing 2025-02-11T10:51:25+00:00 hourly 0.9 https://trial.medpath.com/news/9ee6638467824d72/enhanced-monofocal-iols-show-promise-as-safe-alternative-for-glaucoma-patients 2025-02-11T10:45:18+00:00 hourly 0.9 https://trial.medpath.com/news/aa404075a4331456/q32-bio-restructures-to-advance-bempikibart-development-for-alopecia-areata-treatment 2025-02-11T10:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/99ac4b5bab581e8e/novel-tb-vaccines-and-ai-driven-solutions-show-promise-in-global-fight-against-tuberculosis 2025-02-11T10:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/d00245a046dfd90d/purdue-innovates-partners-with-biobond-to-advance-novel-material-technologies-commercialization 2025-02-11T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe6665eb1e51ae7b/breast-cancer-rates-rise-disproportionately-among-minority-women-seer-data-shows 2025-02-11T08:29:27+00:00 hourly 0.9 https://trial.medpath.com/news/3e02465908166d69/fda-approves-ibex-s-ai-powered-software-for-prostate-cancer-detection-with-99-6-accuracy 2025-02-11T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7dc1cf9c798ceb13/novo-nordisk-seeks-ema-approval-for-first-oral-glp-1-diabetes-treatment 2025-02-11T07:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/51cedaa342ad1ff0/inspira-s-bio-electronic-patch-shows-95-efficacy-in-preventing-bloodstream-infections 2025-02-11T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6471668c7a81a2d3/racial-disparities-persist-in-triple-negative-breast-cancer-trials-despite-treatment-advances 2025-02-11T06:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/1ed074b741e6a730/stellaromics-raises-new-funding-to-pioneer-3d-spatial-biology-platform-for-cancer-and-neuroscience-research 2025-02-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/97c15c6c2c1939d4/nih-trial-shows-home-based-peanut-butter-therapy-successfully-treats-high-threshold-peanut-allergies 2025-02-11T04:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/4e8c6010096fea16/merck-kgaa-in-advanced-talks-to-acquire-springworks-therapeutics-bridgebio-secures-eu-approval-for-attr-drug 2025-02-11T03:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e184594c3c2661a/michigan-study-reveals-working-past-65-boosts-physical-and-mental-health-outcomes 2025-02-11T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/340e461da536cc4a/padcev-keytruda-combination-shows-sustained-survival-benefit-in-advanced-urothelial-cancer-trial 2025-02-11T02:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/d73b7e029361d641/clearside-s-cls-ax-phase-2b-trial-data-shows-promise-in-treatment-naive-amd-patients 2025-02-11T02:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/cd0bc7a6039b6e30/md-anderson-reports-breakthrough-in-metastatic-prostate-cancer-treatment-with-targeted-therapy 2025-02-11T01:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/619e96001f8b3e0a/conv01-a-combination-therapy-shows-29-8-month-survival-in-advanced-prostate-cancer-trial 2025-02-11T01:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/40268b45196f0075/clinical-trial-sites-face-growing-technology-burden-as-industry-pushes-for-greater-diversity-and-efficiency 2025-02-11T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d7fc3d41ea2fbef5/higher-dose-two-session-vaginal-brachytherapy-proves-effective-for-endometrial-cancer-treatment 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c905ab8013d195e/oragenics-and-brainbox-solutions-partner-to-develop-first-integrated-concussion-diagnosis-and-treatment-platform 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe8d513522ec9cfa/pnkp-inhibitor-shows-promise-in-enhancing-radiation-therapy-for-colorectal-cancer 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ebc81fe3d79397ac/gut-microbiome-profile-determines-broccoli-sprout-extract-s-effectiveness-in-prediabetes-treatment 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/71a35554251a0556/fda-approves-novel-treatment-for-rare-genetic-lipid-disorder-familial-chylomicronemia-syndrome 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/701864bdfa426ea1/novel-therapies-show-promise-in-reshaping-frontline-metastatic-rcc-treatment-landscape 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/773ffb709bc869c1/cognitive-processing-therapy-shows-superior-efficacy-for-ptsd-treatment-in-landmark-japanese-study 2025-02-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/68887f083276ecb3/double-dose-dolutegravir-shows-promise-in-reducing-hiv-viral-reservoir 2025-02-10T22:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/9a8866b1be91a837/novel-car-t-cell-therapy-shows-97-response-rate-in-advanced-multiple-myeloma-trial 2025-02-10T22:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/18e2c840613208d9/hku-develops-revolutionary-oral-arsenic-treatment-for-rare-blood-cancer-with-97-cure-rate 2025-02-10T22:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/668c5e0c7b3eefe2/eu-expands-covid-19-vaccine-options-new-protein-based-vaccines-join-mrna-offerings-for-2024 2025-02-10T22:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/0fe47ae63dca6fe5/phase-3-trial-shows-delgocitinib-cream-effective-for-adolescent-chronic-hand-eczema 2025-02-10T22:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/cc05fb3c564e5a14/triple-combination-of-envafolimab-suvemcitug-and-folfiri-shows-promise-in-advanced-colorectal-cancer 2025-02-10T22:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/204db71e4057244a/inventiva-restructures-to-focus-on-mash-drug-development-reports-eur96-6m-year-end-cash-position 2025-02-10T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/2ad5807d7fac4c1c/novel-cd28-x-nectin-4-bispecific-antibody-shows-promise-in-advanced-bladder-cancer-treatment 2025-02-10T22:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8d6e9209ea1cce5/narsoplimab-shows-promising-real-world-outcomes-in-ta-tma-patients-at-2025-tandem-meetings 2025-02-10T20:01:44+00:00 hourly 0.9 https://trial.medpath.com/news/f678778665d37446/comprehensive-genomic-analysis-reveals-key-metastatic-pathways-and-drug-targets-in-thyroid-cancer 2025-02-10T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f0b95290ec1cf2aa/cel-sci-advances-multikine-for-head-and-neck-cancer-with-fda-cleared-212-patient-registration-study 2025-02-10T19:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/a3fb0a2685e70278/study-reveals-gender-gap-in-post-stroke-cardiac-care-women-receive-less-monitoring-and-fewer-cardiology-referrals 2025-02-10T19:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/f7b115ffd0c3e8e5/radiopharm-s-novel-brain-metastases-imaging-agent-shows-100-detection-rate-in-clinical-study 2025-02-10T19:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/1c3a0b8711bb81e7/taurx-secures-119-million-investment-as-novel-tau-targeting-alzheimer-s-drug-advances-toward-regulatory-filing 2025-02-10T17:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/acc32f093a0e2d26/nls-pharmaceutics-and-newamsterdam-pharma-file-mixed-securities-shelves-worth-75m-and-500m-respectively 2025-02-10T16:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/83ce1d46213a3b93/lonsurf-shows-promising-survival-benefits-for-stage-4-colorectal-cancer-patients-with-molecular-residual-disease 2025-02-10T16:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/7b8ec81b051532c5/inovio-to-present-ino-3107-hpv-treatment-data-showing-complete-viral-clearance-at-aacr-io-conference 2025-02-10T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/7f5db91e4d1a4eb5/ocean-biomedical-s-novel-cancer-immunotherapy-shows-promise-in-reversing-egfr-tki-resistance-in-lung-cancer 2025-02-10T16:35:18+00:00 hourly 0.9 https://trial.medpath.com/news/c7d28b219bb0f793/fda-grants-fast-track-status-to-erapa-for-familial-adenomatous-polyposis-treatment 2025-02-10T16:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/cff6f7914e267b8f/greenwich-lifesciences-reports-46-hla-a-02-prevalence-in-flamingo-01-trial-for-breast-cancer-vaccine 2025-02-10T16:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/53d28d5ae1faaca8/incyte-reports-strong-2024-growth-with-4-2b-revenue-outlines-ambitious-2025-pipeline-milestones 2025-02-10T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/9849808a05041915/washu-medicine-launches-groundbreaking-trial-of-remternetug-to-prevent-early-onset-alzheimer-s 2025-02-10T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/baf752607d282cd0/bcg-shortage-continues-to-shape-bladder-cancer-treatment-landscape-despite-new-therapy-approvals 2025-02-10T16:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/11a7630805ddb66e/fda-approvals-expand-amivantamab-s-role-in-egfr-mutated-nsclc-treatment 2025-02-10T16:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/e4bd1caff3461e6b/tirzepatide-shows-promising-renal-benefits-in-type-2-diabetes-patients-through-surpass-trials-analysis 2025-02-10T16:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/40abf07724fb1756/iview-therapeutics-novel-dry-eye-treatment-shows-promising-results-in-phase-1-2-trial 2025-02-10T16:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/400617e3f6f9bd95/bharat-biotech-subsidiary-launches-world-s-first-diva-marker-lumpy-skin-disease-vaccine 2025-02-10T14:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/ceae4dcf214a2c47/study-reveals-superior-survival-outcomes-for-cll-and-mcl-patients-at-academic-cancer-centers 2025-02-10T14:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/e50a2eaaff3c5895/pliant-therapeutics-halts-ipf-drug-trial-following-safety-concerns-stock-plummets 2025-02-10T14:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/83bbb7fdf88dde07/pliant-therapeutics-halts-beacon-ipf-trial-following-safety-board-review 2025-02-10T14:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/f813ab5b1235b72b/inmune-bio-plans-fda-submission-for-cordstrom-in-rare-skin-disease-rdeb 2025-02-10T14:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/b79a328d5ee899b3/phase-3-trial-success-gtx-104-shows-promise-in-treating-brain-hemorrhage-with-reduced-hypotension-risk 2025-02-10T13:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/c129312d839b95a0/actuate-therapeutics-elraglusib-shows-promise-in-pancreatic-cancer-as-ipo-lock-up-expires 2025-02-10T13:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/d9a5af76efe87db2/olix-and-eli-lilly-forge-630m-deal-for-novel-rnai-therapy-targeting-mash-and-obesity 2025-02-10T13:35:43+00:00 hourly 0.9 https://trial.medpath.com/news/b5aa088e5d57fa11/fda-approves-shanghai-henlius-biotech-s-novel-als-drug-hlx99 2025-02-10T13:35:27+00:00 hourly 0.9 https://trial.medpath.com/news/648e8bb89faa60e2/scotland-rejects-lecanemab-for-nhs-coverage-citing-cost-and-benefit-uncertainties 2025-02-10T13:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/e8e82592bf7541b8/cardiogeni-secures-ps20m-investment-for-heart-failure-drug-trials-in-uae-partnership 2025-02-10T13:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/73f0560c8f206246/plasmid-dna-manufacturing-market-set-to-reach-11-33-billion-by-2034-amid-gene-therapy-boom 2025-02-10T13:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/f65fbb802811f7f9/vertex-coo-stuart-arbuckle-to-retire-company-announces-key-leadership-changes 2025-02-10T12:42:53+00:00 hourly 0.9 https://trial.medpath.com/news/184bbb4dd93cb47c/orca-t-cell-therapy-shows-superior-outcomes-in-phase-3-trial-for-blood-cancer-patients 2025-02-10T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/835a7e864b0b3db3/medicare-part-b-psychiatrist-coverage-drops-16-8-despite-growing-mental-health-workforce 2025-02-10T12:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/daad8abf6d93ff71/fda-outlines-requirements-for-mmj-002-first-natural-cannabis-drug-for-huntington-s-disease 2025-02-10T11:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/3f25c3602df2e3b3/medincell-s-olanzapine-lai-phase-3-trial-completes-triggering-5m-milestone-payment-from-teva 2025-02-10T11:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/6616a08ee1fd8382/bictegravir-ftc-taf-shows-efficacy-in-hiv-patients-with-nrti-resistance-after-pi-based-therapy-switch 2025-02-10T11:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/621f4feb1fd8f2e1/bioray-s-novel-dual-epitope-adc-drug-br111-advances-to-clinical-trials-for-cancer-treatment 2025-02-10T11:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/e844fa1c46d10448/pyc-therapeutics-advances-novel-kidney-drug-to-first-human-clinical-trials 2025-02-10T11:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/5a2df46ef3c1886b/esmo-guidelines-include-sugemalimab-as-first-line-nsclc-therapy-marking-major-treatment-advancement 2025-02-10T11:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/59bc9f69c7b50d3e/cbl-514-shows-promising-results-in-phase-2b-trial-for-non-surgical-fat-reduction 2025-02-10T11:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/8585ba656505d220/acelink-s-oral-gcs-inhibitor-shows-promising-phase-2-results-in-fabry-disease-treatment 2025-02-10T11:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/35e50d01bc115787/uk-mhra-approves-winlevi-r-first-novel-acne-treatment-in-40-years 2025-02-10T11:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/bda738c16f739ae5/fda-approves-sanofi-s-enjaymo-first-targeted-therapy-for-rare-blood-disorder-cad 2025-02-10T11:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/66f776c70714845f/gyder-surgical-secures-fda-clearance-for-novel-hip-replacement-navigation-system 2025-02-10T11:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/369a2db56d0c5c91/seragem-s-master-v7-massage-device-receives-fda-approval-for-multiple-therapeutic-indications 2025-02-10T11:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/35a624439e14c953/medpacto-advances-vactosertib-to-phase-2-trial-for-pediatric-osteosarcoma-treatment-in-us 2025-02-10T11:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/5b1d05e96dadb4bd/tegoprubart-successfully-used-in-second-pig-to-human-kidney-xenotransplant-at-mgh 2025-02-10T11:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/5fe32a1551433404/amneal-launches-generic-ezetimibe-competing-with-2-7b-zetia-market 2025-02-10T11:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/0071bf0ee79822b7/modified-short-course-tb-treatment-shows-79-success-rate-in-dominican-republic-study 2025-02-10T11:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/06e24d684b4cead9/jak-inhibitors-show-promising-long-term-safety-and-efficacy-in-atopic-dermatitis-treatment-yale-expert-reports 2025-02-10T11:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/e6f80e34cfe4aae3/st-joseph-s-candler-pioneers-novel-dosing-study-for-metastatic-breast-cancer-treatment 2025-02-10T11:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/0938b5e3d33490d4/hhs-communication-freeze-disrupts-clinical-trials-and-public-health-updates-senators-demand-immediate-action 2025-02-10T11:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/f726508c2fea0fde/luzhu-biotech-s-novel-herpes-zoster-vaccine-advances-as-nmpa-accepts-regulatory-filing 2025-02-10T10:59:41+00:00 hourly 0.9 https://trial.medpath.com/news/0ffd719d82c3d483/mangoceuticals-advances-h1n1-study-and-expands-research-to-h5n1-influenza 2025-02-10T10:59:25+00:00 hourly 0.9 https://trial.medpath.com/news/62070e60430a5cc9/wvu-medicine-leads-groundbreaking-trial-of-endoscopic-procedure-to-maintain-glp-1-weight-loss 2025-02-10T10:59:03+00:00 hourly 0.9 https://trial.medpath.com/news/2a107c13fc9e5af1/neuralink-s-brain-computer-interface-shows-promise-after-one-year-three-patients-regain-digital-control 2025-02-10T10:58:44+00:00 hourly 0.9 https://trial.medpath.com/news/28da9e20883e9c60/pembrolizumab-shows-promise-in-advanced-clear-cell-gynecologic-cancer-peacocc-trial-reports 2025-02-10T10:58:24+00:00 hourly 0.9 https://trial.medpath.com/news/71d31d806d557c6b/extended-time-window-for-alteplase-shows-breakthrough-results-in-late-stage-stroke-treatment 2025-02-10T10:58:01+00:00 hourly 0.9 https://trial.medpath.com/news/3938f0a64f636268/gain-therapeutics-to-present-phase-1-data-for-novel-parkinson-s-drug-gt-02287-at-mjff-conference 2025-02-10T10:56:36+00:00 hourly 0.9 https://trial.medpath.com/news/81eaa0212e3d5afc/clinical-trials-support-immunotherapy-first-approach-in-advanced-braf-melanoma-treatment 2025-02-10T10:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/fae04e6445f4e2f6/novel-nasal-spray-cyr-064-enters-trial-for-parkinson-s-related-smell-loss 2025-02-10T10:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/125631d06522db30/faron-pharmaceuticals-secures-eur12m-to-advance-promising-mds-treatment-bexmarilimab 2025-02-10T10:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/3158da4594b4c4e0/adjuvant-pd-1-inhibitors-show-promise-in-stage-iib-c-melanoma-treatment-keynote-716-and-checkmate-76k-trials-reveal 2025-02-10T10:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/c9c42e4bb6755c34/dana-farber-s-experimental-kidney-cancer-vaccine-shows-lasting-protection-after-three-years 2025-02-10T10:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/c80bb6f60ca51123/vetigenics-secures-6m-seed-funding-to-advance-pet-focused-antibody-therapeutics-pipeline 2025-02-10T10:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/6169e8c457d5d2d1/escape-mevo-trial-endovascular-thrombectomy-shows-no-added-benefit-for-medium-vessel-occlusion-stroke 2025-02-10T10:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/7f4a4d438ecc7b5e/ai-in-oncology-leading-oncologist-outlines-vision-for-clinician-ai-partnership-in-cancer-care 2025-02-10T10:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f1feae3dab54cc9/patient-journey-highlights-evolution-in-egfr-mutated-nsclc-treatment-landscape 2025-02-10T10:50:55+00:00 hourly 0.9 https://trial.medpath.com/news/b1303ba6da896da4/toleranzia-secures-swedish-regulatory-approval-for-tol2-clinical-trial-in-myasthenia-gravis 2025-02-10T10:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/2b67388afa12b7c7/eleva-partners-with-3pbiovian-to-scale-production-of-novel-complement-modulator-for-rare-diseases 2025-02-10T10:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/7ff4ad24335f4a84/stanford-study-reveals-origins-of-post-car-t-myeloid-neoplasms-suggesting-similarities-to-known-treatment-related-malignancies 2025-02-10T10:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/d84f5ce36d24b0da/fda-grants-orphan-drug-designation-to-mb-105-for-cd5-blood-cancer-treatment 2025-02-10T10:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/ae4735a021535783/conduit-pharmaceuticals-advances-to-phase-ii-of-ai-driven-drug-development-partnership 2025-02-10T10:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/f6cd56f3fb3f11e9/alumis-and-acelyrin-announce-merger-deal-suspend-phase-iii-plans-for-lonigutamab 2025-02-10T10:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/de9047c235ad38a5/eyp-1901-shows-promise-in-wet-amd-and-dme-trials-with-significant-reduction-in-treatment-burden 2025-02-10T10:47:10+00:00 hourly 0.9 https://trial.medpath.com/news/429731c44f817951/long-term-safety-study-shows-comparable-colectomy-rates-between-golimumab-and-other-anti-tnf-therapies-in-ulcerative-colitis 2025-02-10T10:46:54+00:00 hourly 0.9 https://trial.medpath.com/news/a5e943a88879838c/fda-approves-lumenis-optilift-novel-device-shows-promise-in-treating-lower-lid-laxity-and-blinking-disorders 2025-02-10T10:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/ed27c89d7f8f19e0/brazilian-trial-compares-metformin-vs-insulin-for-gestational-diabetes-management 2025-02-10T10:46:21+00:00 hourly 0.9 https://trial.medpath.com/news/7ac75c992e762a21/dha-launches-groundbreaking-platform-trial-to-evaluate-multiple-ptsd-treatments-for-military-personnel 2025-02-10T10:42:44+00:00 hourly 0.9 https://trial.medpath.com/news/06fbd6cc62506149/hlb-advances-cancer-drug-pipeline-rivoceranib-fda-decision-due-march-plans-rly-4008-development 2025-02-10T10:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bab008fd1af0147/replicate-s-single-dose-rna-rabies-vaccine-shows-promise-in-phase-i-trial 2025-02-10T10:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/4b32ad9074c24392/photopharmics-reaches-50-enrollment-milestone-in-phase-3-trial-testing-light-therapy-for-parkinson-s-disease 2025-02-10T10:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/5e44d6656cdb117f/epcore-nhl-2-trial-shows-promise-combining-chemotherapy-and-immunotherapy-for-dlbcl 2025-02-10T10:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/5f802151287d8779/ema-issues-new-guidelines-for-clinical-development-of-advanced-therapy-medicinal-products 2025-02-10T10:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/271cece58e0c9a99/fda-approves-novel-antibiotic-combination-emblaveo-for-complex-abdominal-infections 2025-02-10T10:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/b47a44e2e85c1baf/scholar-rock-seeks-fda-approval-for-novel-sma-add-on-therapy-apitegromab 2025-02-10T10:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/8649bc182636e625/fda-approves-orlynvahtm-first-new-oral-treatment-for-uncomplicated-utis-in-25-years 2025-02-10T10:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/ccb5e63a5bb33407/novo-nordisk-s-mim8-shows-promise-in-phase-iii-pediatric-hemophilia-a-trial 2025-02-10T10:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/508542baeb83779b/novel-bispecific-antibody-kn046-plus-lenvatinib-shows-promise-in-advanced-liver-cancer-treatment 2025-02-10T10:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/991e74d2a5efb4a3/spectral-ai-completes-pivotal-burn-study-analysis-plans-fda-de-novo-submission-for-ai-powered-wound-assessment-system 2025-02-10T10:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/4213439956bde713/first-patient-receives-novel-stem-cell-therapy-in-groundbreaking-sjogren-s-disease-trial 2025-02-10T10:29:21+00:00 hourly 0.9 https://trial.medpath.com/news/8ef932402f47d3e5/telemedicine-based-lifestyle-intervention-shows-limited-benefits-for-patients-with-chd-and-type-2-diabetes 2025-02-10T10:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/ed021e76823f039a/quince-therapeutics-phase-3-neat-trial-for-ataxia-telangiectasia-reaches-50-enrollment-milestone 2025-02-10T10:28:33+00:00 hourly 0.9 https://trial.medpath.com/news/b46582aede4c11aa/xairos-secures-1-9m-spacewerx-contract-for-quantum-optical-timing-system-development 2025-02-10T10:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/5eb703cbee4f49c5/conduit-pharmaceuticals-advances-ai-driven-drug-development-through-phase-ii-sarborg-collaboration 2025-02-10T10:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/90a79fc8c113c257/glp-1-drug-semaglutide-shows-promise-in-alcohol-addiction-treatment-study-at-cu 2025-02-10T10:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/0bb777fe30fce83c/ema-accepts-bio-thera-s-marketing-application-for-bat2506-first-chinese-developed-golimumab-biosimilar 2025-02-10T10:26:43+00:00 hourly 0.9 https://trial.medpath.com/news/e7c05aec9e1e423c/rns60-shows-promising-results-in-phase-2-stroke-trial-reducing-brain-tissue-loss-by-50 2025-02-10T10:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/135f81327678b4d5/zenas-biopharma-launches-phase-2-trial-of-novel-b-cell-targeting-therapy-for-relapsing-ms 2025-02-10T10:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/fe5e9d9092c6f895/alivedx-submits-fda-510-k-application-for-novel-celiac-disease-multiplex-diagnostic-array 2025-02-10T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0e9e96f2ffbde394/foresee-pharmaceuticals-to-present-phase-3-katana-studies-of-novel-prostate-cancer-treatment-at-asco-gu-2025 2025-02-10T08:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/6817c207ce828d60/alterity-therapeutics-secures-a-40m-funding-to-accelerate-msa-drug-development 2025-02-10T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/274f17e51881ddb2/ai-revolution-in-drug-discovery-computing-power-poised-to-transform-pharmaceutical-development 2025-02-10T07:17:40+00:00 hourly 0.9 https://trial.medpath.com/news/5d9e18f7778b86f5/experts-chart-future-direction-of-marginal-zone-lymphoma-research-at-2024-workshop 2025-02-10T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2f5529415744af05/sebetralstat-shows-promise-as-first-oral-treatment-for-hae-attacks-including-breakthrough-episodes-during-prophylaxis 2025-02-10T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8283aabf7572af55/fda-approves-clinical-trials-for-first-ever-treatment-of-jordan-s-syndrome-a-rare-neurodevelopmental-disorder 2025-02-10T06:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ebdb8acdf89f36d/meta-analysis-reveals-optimal-antibiotic-treatments-for-acute-pyelonephritis 2025-02-10T06:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/e9a0c9d0e8dd067c/study-reveals-major-disparities-in-us-health-plan-coverage-of-pharmacogenetic-testing 2025-02-10T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a3f8364a45a8c079/beyond-air-reports-34-revenue-growth-and-expands-global-market-access-with-ce-mark-for-lungfit-ph 2025-02-10T04:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/3fb6dc674d5ccd8c/cleveland-clinic-launches-clinical-trial-of-novel-psychedelic-for-postpartum-depression 2025-02-10T02:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/4f752effd77c3a98/adipose-derived-stem-cell-injections-show-promise-in-treating-inflammatory-eye-diseases 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a12d54b2e8fbe39e/bimzelx-s-novel-dual-il-17-inhibition-mechanism-drives-five-fda-approvals-across-inflammatory-conditions 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/87bdf725241f46ac/fda-grants-accelerated-approval-to-ipsen-s-iqirvo-first-dual-ppar-agonist-for-primary-biliary-cholangitis 2025-02-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb9d5e569de6a33d/diagnostic-testing-emerges-as-critical-success-factor-in-adc-development-for-cancer-treatment 2025-02-09T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/42cd099fb0325275/targeted-therapies-and-immunotherapy-advances-in-non-small-cell-lung-cancer-a-comprehensive-review 2025-02-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b8ab1c6069e65608/national-study-shows-equal-effectiveness-of-different-dementia-care-delivery-models 2025-02-09T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/1b791a3fa0bce761/study-reveals-clinical-trials-underestimate-quality-of-life-impact-in-relapsed-refractory-multiple-myeloma 2025-02-09T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/45552404c67a3513/global-study-reveals-critical-underutilization-of-secondary-prevention-medications-for-cardiovascular-disease 2025-02-09T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/36552f36dbb6be51/ai-machine-learning-models-show-promise-in-predicting-ckd-progression-to-kidney-failure 2025-02-09T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e51cc92a2e0e0a3e/deciphera-s-qinlock-fails-phase-3-trial-in-second-line-gist-shares-plummet-75 2025-02-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b00c4e7bbdc9d1d/roche-launches-skyline-four-year-prevention-trial-for-gantenerumab-in-early-stage-alzheimer-s 2025-02-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a181a78cae221d50/motion-control-running-shoes-reduce-injury-risk-in-runners-with-pronated-feet-study-shows 2025-02-08T17:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/a88b19a8835b21ee/usaid-funding-freeze-threatens-hiv-treatment-programs-across-africa 2025-02-08T12:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8b304bb7ecd41e5/experts-highlight-critical-link-between-schizophrenia-and-substance-use-disorders-call-for-integrated-treatment-approach 2025-02-08T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ee29506f822a4a0/fda-grants-breakthrough-device-designation-to-onc-ai-s-ai-powered-cancer-prognosis-tool 2025-02-08T00:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/bf11619993e25356/lecanemab-shows-27-cognitive-decline-reduction-in-alzheimer-s-trial-safety-concerns-emerge 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/84cc08876a054327/ema-s-chmp-recommends-approval-of-novartis-jetrea-for-vitreomacular-traction-treatment 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0fb1a8b6d43ab97f/merck-and-pfizer-launch-competitively-priced-sglt2-inhibitor-steglatro-for-type-2-diabetes 2025-02-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/31289de4698c5703/sun-pharma-and-philogen-complete-enrollment-for-pivotal-phase-iii-fibrosarc-trial-in-soft-tissue-sarcoma 2025-02-07T23:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/f6c83e1ac0f4fdb1/tevogen-bio-presents-exactcell-platform-to-barda-as-potential-rapid-response-viral-countermeasure 2025-02-07T20:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/1d0155d08cecff9f/african-genetic-diversity-opens-new-frontiers-in-global-precision-medicine-research 2025-02-07T17:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/a9afd5e2fda14226/tnx-1500-shows-promising-safety-profile-in-phase-i-trial-for-transplant-recipients 2025-02-07T16:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e3343a276679335/novel-adar1-inhibitor-rebecsinib-shows-promise-in-halting-cancer-progression-through-space-based-research 2025-02-07T15:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/0d67f7a702d49d46/study-reveals-8-7-of-pediatric-patients-lost-medicaid-coverage-during-unwinding-period 2025-02-07T14:00:36+00:00 hourly 0.9 https://trial.medpath.com/news/a85f95cf55aa2d33/ct-imaging-predicts-surgical-benefits-of-neoadjuvant-tki-therapy-in-non-metastatic-gist-patients 2025-02-07T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/e4f8fa0b1ca4172d/sclc-incidence-drops-50-over-two-decades-while-survival-rates-remain-stagnant-seer-analysis-shows 2025-02-07T13:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/13df77443ea940fa/fasting-plasma-glucose-emerges-as-key-predictor-in-10-year-diabetes-risk-assessment-study 2025-02-07T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d172d34c23194917/replicate-bioscience-s-novel-srrna-rabies-vaccine-shows-promise-in-first-human-trial 2025-02-07T12:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/72b0845e51bc4f5c/electronic-symptom-monitoring-system-reduces-emergency-visits-and-improves-quality-of-life-in-cancer-patients 2025-02-07T11:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/98ee57971022599b/ultrasensitive-dna-detection-shows-promise-in-b-cell-lymphoma-remission-assessment 2025-02-07T11:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/5f3e8c4998ec375c/turnstone-biologics-discontinues-tidal-01-development-program-for-solid-tumors-despite-early-promise 2025-02-07T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/006e56afdc72dc10/gazyva-shows-significant-improvement-in-lupus-nephritis-treatment-phase-iii-regency-trial-results 2025-02-07T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/e550afc223de4827/study-reveals-higher-emergency-admissions-and-longer-hospital-stays-for-cancer-patients-with-dementia 2025-02-07T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f64f423be5ff6999/bluewind-medical-s-revi-r-system-shows-sustained-efficacy-for-urinary-incontinence-at-two-year-mark 2025-02-07T09:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5d9b6e70ec992a1/surgical-treatment-for-keratinocyte-skin-cancer-proves-safe-in-octogenarians-swiss-study-shows 2025-02-07T09:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/994803d8b558298d/mobile-eye-clinic-innovation-streamlines-phase-1-trial-safety-assessments 2025-02-07T08:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/f692e475ebc2ecfd/tht-2025-groundbreaking-heart-failure-clinical-trials-to-be-presented-at-crf-conference 2025-02-07T08:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/6892223f0b88ed9f/fda-grants-priority-review-to-brensocatib-for-non-cystic-fibrosis-bronchiectasis-treatment 2025-02-07T08:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/e24e70276f9f9b6a/astrazeneca-s-bydureon-fails-to-slow-parkinson-s-disease-progression-in-phase-iii-trial 2025-02-07T08:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/83076c22034668bd/cero-therapeutics-secures-5m-funding-advances-novel-cer-t-cell-therapy-towards-phase-1-trial 2025-02-07T08:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/904aee8faf3abca6/major-icu-trial-tests-high-protein-enteral-formula-in-critical-care-patients-across-australia-and-new-zealand 2025-02-07T08:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/6376fcf62c76d4ee/vaxcyte-advances-31-valent-pneumococcal-vaccine-to-final-phase-ii-stage-in-infant-trial 2025-02-07T08:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/5d3fe5eb10c3e7d2/recursion-s-ai-discovered-drug-shows-promise-in-phase-ii-brain-disease-trial 2025-02-07T08:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/66e99f050815c888/venovalve-shows-sustained-benefits-in-two-year-follow-up-data-from-u-s-pivotal-trial 2025-02-07T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/7634e0205458ca65/primary-care-practices-show-mixed-evolution-post-covid-enhanced-capabilities-but-reduced-access 2025-02-07T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8fb8e65729fae004/novel-t-cell-therapy-trial-aims-to-reduce-post-transplant-relapse-in-blood-cancer-patients 2025-02-07T07:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/a563f9edb1e1d851/aim-immunotech-advances-ampligen-study-as-potential-avian-flu-vaccine-booster-with-promising-cross-protection 2025-02-07T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/8809039327d151e1/long-term-multiple-myeloma-survivors-show-better-outcomes-in-landmark-us-registry-analysis 2025-02-07T07:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/e26954d96c8ac348/fda-extends-review-period-for-eton-pharmaceuticals-rare-disease-drug-et-400 2025-02-07T06:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/64e68692a2264e03/novel-non-hormonal-hair-loss-treatment-vdphl01-enters-phase-2-3-clinical-trials 2025-02-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2237026044198975/study-links-pro-inflammatory-diet-to-higher-youth-hypertension-risk-in-nhanes-analysis 2025-02-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8cd654ac9f4d3ab3/large-scale-study-confirms-safety-of-car-t-cell-therapy-no-link-to-secondary-cancers-found 2025-02-07T04:53:05+00:00 hourly 0.9 https://trial.medpath.com/news/e074889e3ff3fd60/renovorx-secures-12-1m-through-public-offering-to-advance-pancreatic-cancer-trial 2025-02-07T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ee26b15260db85f/bain-capital-acquires-mitsubishi-tanabe-pharma-in-3-3-billion-deal 2025-02-07T02:52:18+00:00 hourly 0.9 https://trial.medpath.com/news/3d2e618edd2a8ee8/healthcare-professionals-express-optimism-for-ai-s-role-in-pharmaceutical-innovation-call-for-ethical-implementation 2025-02-07T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c74abc992a48755d/fda-requests-additional-phase-3-trial-for-santhera-s-dmd-drug-raxone-delaying-approval 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f1074aebd04b0e20/gastrointestinal-organoids-advance-colorectal-cancer-research-through-enhanced-disease-modeling-and-drug-screening 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2c97858b7112ac51/dupilumab-shows-limited-success-in-peanut-allergy-desensitization-study 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a6166d457cbc7120/protara-therapeutics-reports-72-complete-response-rate-in-nmibc-trial-secures-100m-funding 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ee0e20bd542b8bf/alumis-and-acelyrin-announce-merger-to-create-737m-clinical-stage-biopharma-company 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/facaf8e187ba490a/tagrisso-shows-higher-cardiac-risk-in-egfr-mutant-lung-cancer-patients-study-reveals 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/753ef9a492bc5005/novel-trial-launches-to-develop-personalized-treatments-for-glioblastoma-patients 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8049177227d228b/meta-analysis-confirms-tafinlar-mekinist-combination-s-efficacy-across-age-groups-in-glioma-treatment 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f6cad89d2f75d606/johns-hopkins-cidid-pioneers-next-generation-of-rapid-diagnostic-tests-for-global-health-impact 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c5dac584aad5d73/nuance-pharma-s-ohtuvayre-receives-first-approval-outside-us-for-copd-treatment-in-macau 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fcf87b39d60f659a/platinum-chemotherapy-shortage-shows-no-impact-on-short-term-mortality-in-advanced-cancer-patients 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/afe6326abb522632/nice-approves-biogen-s-vumerity-for-relapsing-remitting-multiple-sclerosis-with-improved-tolerability-profile 2025-02-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5372ac7ec71cc7af/flatiron-health-and-exact-sciences-launch-major-study-to-validate-novel-cancer-recurrence-test 2025-02-06T23:51:25+00:00 hourly 0.9 https://trial.medpath.com/news/1ebf1dfc673cd224/genmab-expands-antibody-pipeline-following-profoundbio-deal-plans-further-acquisitions 2025-02-06T23:44:44+00:00 hourly 0.9 https://trial.medpath.com/news/4262d07cad88a586/astrazeneca-reports-robust-21-revenue-growth-in-2024-projects-strong-pipeline-momentum-for-2025 2025-02-06T22:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/513e2b8eec1d6f70/washu-s-novel-nasal-covid-19-vaccine-advances-to-u-s-phase-1-clinical-trials 2025-02-06T22:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/1de0300cf8dca4c0/serina-therapeutics-secures-10m-for-novel-parkinson-s-drug-delivery-system-trial 2025-02-06T21:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/16d5f7df79de1c6d/senseonics-seeks-ce-mark-for-revolutionary-one-year-implantable-glucose-monitor 2025-02-06T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/284c28c1c4d4112b/fda-grants-rmat-designation-to-gradalis-personalized-immunotherapy-for-advanced-ovarian-cancer 2025-02-06T21:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/7855a1a043118098/aim-vaccine-s-mrna-rsv-vaccine-advances-to-u-s-clinical-trials-with-promising-preclinical-data 2025-02-06T21:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/d06e26032577d21e/brain-stimulation-shows-no-added-benefit-for-post-stroke-motor-recovery-in-phase-2-transport-2-trial 2025-02-06T20:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/eb767eb1e350962c/akeso-completes-enrollment-for-phase-iii-trial-of-ivonescimab-in-squamous-nsclc 2025-02-06T20:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/533ea65466b36b90/phase-3-estimabl2-trial-thyroidectomy-without-radioiodine-shows-noninferiority-in-low-risk-thyroid-cancer 2025-02-06T19:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/77bdde7634394051/personalized-vaccine-shows-promise-in-advanced-kidney-cancer-trial-with-100-response-rate 2025-02-06T19:01:02+00:00 hourly 0.9 https://trial.medpath.com/news/6a24acaaba74ed24/novavax-pursues-full-fda-licensure-for-covid-19-vaccine-advancing-from-eua-status 2025-02-06T18:47:20+00:00 hourly 0.9 https://trial.medpath.com/news/bc452eac6f8c4ca4/recursion-s-rec-994-shows-promise-in-phase-ii-trial-for-cerebral-cavernous-malformations 2025-02-06T17:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/ba95aa8dd8e9586c/sangamo-s-gene-therapy-shows-sustained-benefits-in-fabry-disease-patients-with-improved-kidney-function 2025-02-06T17:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/837eac15af5b40d9/itolizumab-shows-promising-results-in-phase-2-ulcerative-colitis-trial-matching-adalimumab-efficacy 2025-02-06T17:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/22088e017fbe949c/astrazeneca-stakes-80-billion-revenue-goal-on-critical-phase-iii-trial-results-in-2024 2025-02-06T16:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/c30066d60d856b84/cirm-awards-5-69m-grant-to-advance-novel-gene-therapy-for-spinocerebellar-ataxia-type-3 2025-02-06T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/b111bbb4f992b05f/shenzhen-zhongge-biotech-advances-development-of-novel-ptpn2-inhibitors 2025-02-06T16:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/c19b92e459aff6f2/opdivo-chemotherapy-combination-shows-promise-for-elderly-hodgkin-lymphoma-patients 2025-02-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/57d3b12eb002a628/kerala-health-initiative-screens-over-1-crore-people-in-major-lifestyle-disease-prevention-drive 2025-02-06T15:46:10+00:00 hourly 0.9 https://trial.medpath.com/news/986793692190721e/kura-oncology-s-menin-inhibitor-ziftomenib-shows-promise-in-mid-stage-cancer-trial 2025-02-06T15:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed7dd319bb61d9b6/astrazeneca-discontinues-two-alexion-rare-disease-programs-amid-strong-q4-performance 2025-02-06T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/10178610a52bd0f7/leronlimab-shows-promising-results-in-reversing-liver-fibrosis-cytodyn-reports 2025-02-06T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/3bc8d3ec0659d6aa/racial-disparities-found-in-pediatric-migraine-diagnosis-and-treatment-across-us-children-s-hospitals 2025-02-06T13:19:46+00:00 hourly 0.9 https://trial.medpath.com/news/07e7c04e732d88d6/fda-grants-fast-track-status-to-bracco-s-br55-ultrasound-agent-for-crohn-s-disease-monitoring 2025-02-06T13:11:47+00:00 hourly 0.9 https://trial.medpath.com/news/44f8380f6e30ae8f/phase-2-trial-for-post-glp-1-weight-management-drug-rdx-002-completes-enrollment-early 2025-02-06T13:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/3a19aeafb6936890/fda-grants-expanded-access-program-for-lipella-s-lp-310-in-oral-lichen-planus-treatment 2025-02-06T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4028ca27b5af1048/ziftomenib-achieves-primary-endpoint-in-pivotal-aml-trial-kura-and-kyowa-kirin-prepare-fda-filing 2025-02-06T12:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/2661dd9c74884347/fda-grants-ide-approval-for-newronika-s-novel-adaptive-deep-brain-stimulation-system-for-parkinson-s-disease 2025-02-06T12:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/3102cc30c7628fde/northwestern-medicine-selected-as-first-site-for-pivotal-clarity-trial-testing-nociscan-s-low-back-pain-technology 2025-02-06T12:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/97311162bde475d2/immuneering-partners-with-regeneron-to-test-novel-cancer-drug-combination-for-advanced-lung-cancer 2025-02-06T12:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ab362cf88e7e53f/protacs-breakthrough-drug-technology-faces-development-hurdles-in-targeting-undruggable-proteins 2025-02-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c39b29198edf2039/recent-clinical-trials-show-promise-of-ketamine-for-rapid-reduction-of-suicidal-ideation 2025-02-06T11:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/af008db71aca2495/novo-nordisk-delays-cagrisema-obesity-drug-filing-to-early-2026 2025-02-06T09:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/e7a863be08fb1e8a/u-s-cell-and-gene-therapy-bioanalytical-testing-market-to-reach-349-million-by-2034 2025-02-06T09:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/fb1849910850f633/expres2ion-biotech-advances-to-clinical-phase-with-her2-breast-cancer-vaccine-reports-strong-q4-2024-progress 2025-02-06T09:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/643f45863cc08be0/gallup-emory-survey-healthcare-access-and-costs-top-americans-public-health-priorities 2025-02-06T08:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/310aa0978027b00f/vaxxas-strengthens-development-team-with-global-vaccine-experts-ahead-of-late-stage-trials 2025-02-06T07:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/cf93e8c777874156/ai-chatbot-matches-standard-care-in-facilitating-cancer-genetic-testing-access-bridge-trial-shows 2025-02-06T07:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/cf668554fd662ccb/sanofi-to-present-extensive-immunology-data-at-aaaai-2025-highlighting-dupixent-and-pipeline-advances 2025-02-06T06:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/dddbc1ff773027e7/sacituzumab-govitecan-shows-promise-in-treating-brain-metastases-and-glioblastoma-in-phase-0-trial 2025-02-06T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9ad5ee965ae4df0/daybue-clinical-trials-show-significant-communication-and-motor-improvements-in-rett-syndrome-patients 2025-02-06T05:58:59+00:00 hourly 0.9 https://trial.medpath.com/news/a374bc1cd60f4357/novavax-s-xbb-1-5-based-covid-19-booster-shows-superior-immune-response-in-phase-2-3-trial 2025-02-06T05:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/fa94eda5fb1c2ea3/fda-requires-additional-efficacy-study-for-lipocine-s-oral-postpartum-depression-treatment-lpcn-1154 2025-02-06T04:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/3aa9d8b473a3b8f2/bristol-myers-squibb-announces-2-billion-cost-cutting-plan-amid-patent-cliff-challenges 2025-02-06T04:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/f24dcd12eb7b8708/eli-lilly-reports-doubled-q4-profits-driven-by-surging-obesity-and-diabetes-drug-sales 2025-02-06T03:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/71a43916642b6249/caris-life-sciences-to-present-novel-cancer-research-at-2025-asco-gu-symposium 2025-02-06T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/de8a53e4a78890fa/next-generation-antibody-drug-discovery-merging-ai-and-functional-screening-to-unlock-novel-therapeutics 2025-02-06T02:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/8cffa8a9ab891f1c/psm-challenges-hims-hers-super-bowl-ad-for-compounded-semaglutide 2025-02-06T02:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/f1d7bbf110c4ee31/spago-nanomedical-advances-tumorad-program-streamlines-operations-for-clinical-development-focus 2025-02-06T02:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/47fa4be15c1ebc0d/qlaris-reports-positive-phase-ii-results-for-qls-111-in-reducing-intraocular-pressure 2025-02-06T01:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/aeb5701159e01cc8/recursion-s-rec-994-shows-promising-safety-and-efficacy-signals-in-phase-2-ccm-trial 2025-02-06T01:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/8e14fc560a622605/belite-bio-secures-15-million-in-direct-offering-to-advance-retinal-disease-therapeutics 2025-02-06T01:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/b8d2740cc39d5426/novel-walk-n-watch-protocol-shows-significant-improvements-in-post-stroke-recovery 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/da4aedddcb877919/bioxcel-therapeutics-advances-phase-3-trials-for-bxcl501-in-agitation-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9bdfa4bc45178813/belite-bio-secures-15-million-through-direct-offering-to-advance-tinlarebant-development 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/152b27f69bcbde00/qureight-s-ai-imaging-platform-to-support-avalyn-s-inhaled-pirfenidone-trial-in-pulmonary-fibrosis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/376b57ff3f5a7af3/enlivex-reports-promising-results-in-phase-i-ii-trial-of-allocetra-for-severe-knee-osteoarthritis 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acbecc991f132dfa/mrd-guided-ibrutinib-venetoclax-therapy-shows-superior-outcomes-in-cll-treatment-flair-trial-results 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4b083bd8f33eff5d/abbvie-and-roche-seek-fda-approval-for-venclexta-gazyva-combination-in-first-line-cll-treatment 2025-02-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/866018b0fc5ea491/pfizer-appoints-former-novartis-executive-jeffrey-legos-as-chief-oncology-officer-to-strengthen-cancer-drug-portfolio 2025-02-05T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/2b3a49ad44e3bd48/hbm-holdings-secures-nmpa-approval-to-begin-copd-drug-trials-in-china 2025-02-05T23:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/bcc4654a4c5c60ad/jupiter-neurosciences-advances-jotrol-platform-with-phase-2a-parkinson-s-trial-and-consumer-product-launch 2025-02-05T23:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/ba19806628ad62e2/large-scale-trial-shows-glp-1-drug-exenatide-ineffective-for-parkinson-s-disease-treatment 2025-02-05T23:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/8e03af3a69377dd6/blinklab-launches-fda-registrational-trial-for-ai-powered-autism-diagnostic-tool 2025-02-05T23:01:32+00:00 hourly 0.9 https://trial.medpath.com/news/ce990df8d6b04811/nhs-launches-ps11m-ai-powered-breast-cancer-screening-trial-involving-700000-women 2025-02-05T23:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/c0e7b50ad0917fcf/fda-clears-cellular-enabled-sansa-home-sleep-apnea-test-eliminating-need-for-smartphone-apps 2025-02-05T22:30:38+00:00 hourly 0.9 https://trial.medpath.com/news/69e39133fa87e694/identiv-and-novanta-partner-to-advance-rfid-technology-in-medical-devices-and-pharmaceuticals 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6947933bf9989765/tinivo-2-trial-shows-no-added-benefit-of-nivolumab-combination-in-io-refractory-rcc-treatment 2025-02-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0660b795e9981de2/respiratory-function-monitoring-improves-supraglottic-airway-device-placement-in-neonates-study-shows 2025-02-05T21:57:46+00:00 hourly 0.9 https://trial.medpath.com/news/a14ce3cf68adce0b/duravyu-shows-promising-results-in-phase-2-verona-trial-for-retinal-diseases 2025-02-05T20:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/2abbd1cc4b621c6e/fda-grants-breakthrough-device-status-to-acrivon-s-ai-powered-cancer-diagnostic-platform 2025-02-05T20:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc8bb7d1841afb3e/usc-secures-10-8m-pcori-grant-to-compare-hip-fracture-surgery-approaches-in-elderly-patients 2025-02-05T20:55:54+00:00 hourly 0.9 https://trial.medpath.com/news/b1d3a9bd659bc033/glucotrack-s-novel-implantable-blood-glucose-monitor-shows-promise-in-first-human-trial 2025-02-05T20:01:05+00:00 hourly 0.9 https://trial.medpath.com/news/bbaf5fb9af790f45/personalized-neoantigen-vaccine-shows-promise-in-renal-cell-carcinoma-clinical-trial 2025-02-05T19:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/e3b7196e00509d17/singapore-reinforces-strict-controls-on-ketamine-nasal-spray-for-depression-treatment 2025-02-05T18:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/6fb502945d624cd0/blinklab-advances-smartphone-based-autism-diagnostic-tool-with-first-u-s-clinical-trial-site 2025-02-05T18:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/6c84daf04aad8a27/cleveland-clinic-abu-dhabi-pioneers-first-gcc-breast-cancer-recurrence-trial-with-astrazeneca 2025-02-05T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/7c614d34fe0f6a8d/miist-therapeutics-secures-7m-seed-funding-for-ultra-rapid-inhaled-drug-delivery-platform 2025-02-05T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/8ca0a16281d4c4a3/fda-places-amgen-s-obesity-drug-amg-513-trial-on-clinical-hold 2025-02-05T17:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/f23f70c8456d4009/macustar-study-validates-novel-endpoints-for-age-related-macular-degeneration-clinical-trials 2025-02-05T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/3da5921325af922a/astellas-seeks-first-japanese-approval-for-geographic-atrophy-treatment-with-avacincaptad-pegol 2025-02-05T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/96d13c46a64aeda6/nutrition-platform-fay-secures-50m-series-b-funding-amid-glp-1-weight-loss-drug-boom 2025-02-05T16:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/72a6ee383a7c6416/merck-faces-strategic-challenges-as-29-5b-keytruda-patent-cliff-approaches-in-2028 2025-02-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/b9ab4c50dc6e90b1/novel-spinal-cord-stimulation-shows-promise-in-treating-spinal-muscular-atrophy 2025-02-05T16:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/156ca135fd4fc00d/fda-and-health-canada-clear-alys-pharmaceuticals-aly-101-for-phase-iia-alopecia-areata-trial 2025-02-05T15:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/e966312597556f93/eyepoint-s-duravyu-shows-promising-results-in-phase-2-dme-trial-with-extended-treatment-duration 2025-02-05T15:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/d9b558d8bd7f3b40/e-star-biotech-initiates-phase-2-trial-of-manp-for-resistant-hypertension-treatment 2025-02-05T15:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/a3db07059b227373/health-canada-approves-expansion-of-decoy20-cancer-immunotherapy-trial 2025-02-05T15:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/794e50ff8bac2a79/fda-grants-breakthrough-device-designation-to-acrivon-s-acr-368-oncosignature-test-for-endometrial-cancer 2025-02-05T15:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/ecc2fac95a7266e6/global-partnership-launches-revolutionary-mrna-vaccine-platform-to-boost-african-manufacturing-independence 2025-02-05T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e5a7b529bfcd259/eu-approves-serplulimab-as-first-anti-pd-1-therapy-for-first-line-es-sclc-treatment 2025-02-05T14:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/486386d8cb97d113/wandercraft-initiates-landmark-trial-for-hands-free-personal-exoskeleton-in-sci-patients 2025-02-05T14:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/8d939d18b2728689/remote-clinical-pharmacists-drive-5-9m-cost-savings-in-community-oncology-study 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/893f2f291257d1c3/novo-nordisk-ceo-expresses-confidence-in-medicare-price-negotiations-for-glp-1-drugs 2025-02-05T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/d62e314ee5791a96/inspira-technologies-enhances-hyla-blood-sensor-with-ai-powered-oxygenation-monitoring 2025-02-05T13:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/d1e781923b65db70/phase-1-trial-shows-promise-for-bms-986354-car-t-cell-therapy-in-multiple-myeloma 2025-02-05T13:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/ca401c19e0e3f556/aim-immunotech-advances-to-phase-2-trial-of-ampligen-imfinzi-combination-for-late-stage-pancreatic-cancer 2025-02-05T13:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/a369b184ba9ad693/2-million-grant-awarded-to-advance-gene-therapy-trial-for-rare-childhood-blindness 2025-02-05T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/08753647891fd9b7/fda-approves-baricitinib-as-first-systemic-treatment-for-severe-alopecia-areata-based-on-phase-3-trial-results 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a6da7b07cc37aaf/city-of-hope-expert-highlights-critical-gaps-in-precision-medicine-implementation-for-cancer-care 2025-02-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8f2aeeec7f273dd2/medicaid-cgt-access-model-s-future-uncertain-amid-policy-changes 2025-02-05T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/9feea32c6572e478/fda-supports-phase-iii-development-of-novel-non-invasive-endometriosis-imaging-test 2025-02-05T12:02:33+00:00 hourly 0.9 https://trial.medpath.com/news/f93d687d0fb39813/novel-synthetic-lethal-approaches-show-promise-in-targeting-mtap-and-smarca4-mutations-in-lung-cancer 2025-02-05T12:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/dfbfece3aa994f63/msd-and-cellbion-partner-to-test-novel-radioligand-immunotherapy-combination-for-advanced-prostate-cancer 2025-02-05T11:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/f3e073c04a6ef580/phase-2-trial-shows-promise-tislelizumab-plus-chemotherapy-demonstrates-strong-results-in-advanced-gastroesophageal-cancer 2025-02-05T11:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/2d70f0c490fd769a/low-dose-glucocorticoids-show-no-benefit-for-skin-fibrosis-in-early-systemic-sclerosis-study 2025-02-05T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9a7853b14501666/algiax-s-novel-non-opioid-ap-325-shows-promise-in-phase-2a-neuropathic-pain-trial 2025-02-05T10:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/59f0da8ff2ab98a1/chmp-backs-durvalumab-for-limited-stage-sclc-following-chemoradiation-success 2025-02-05T10:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/be672416fe9c83de/fda-approves-susvimo-for-diabetic-macular-edema-first-continuous-delivery-ranibizumab-treatment 2025-02-05T10:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/e09b2508f2a0d611/gene-therapy-for-wiskott-aldrich-syndrome-under-ema-review 2025-02-05T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/77cc5fcec50b214d/ema-approves-neurotherapia-s-phase-2-trial-for-novel-alzheimer-s-drug-ntrx-07 2025-02-05T10:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/154e5332628d74c1/united-therapeutics-completes-enrollment-in-pivotal-teton-1-trial-for-ipf-treatment 2025-02-05T10:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/3e47db0141338450/gsk-raises-2031-revenue-target-to-ps40-billion-despite-zantac-impact-on-profits 2025-02-05T09:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/b46a77b14e15903e/sernova-files-ind-for-novel-bio-hybrid-thyroid-treatment-advancing-cell-pouch-technology-beyond-diabetes 2025-02-05T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/25f6776b4a77ed5a/turnstone-biologics-halts-tidal-01-development-explores-strategic-alternatives-amid-financial-constraints 2025-02-05T08:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/71822d9c9aa7f917/lantheus-to-present-new-pylarify-data-for-early-prostate-cancer-detection-at-asco-gu-2025 2025-02-05T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/22c32c7025c846e0/european-clinical-trial-supply-conference-2025-to-focus-on-ai-integration-and-supply-chain-innovation 2025-02-05T08:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/32aaee82e92194a0/gsk-raises-five-year-revenue-target-to-ps40bn-following-strong-specialty-medicines-growth 2025-02-05T07:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d1c088963704685/viking-therapeutics-advances-novel-oral-glp-1-gip-dual-agonist-vk2735-to-phase-2-trial-for-obesity-treatment 2025-02-05T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/c2e7103ef7d70fec/china-s-bnct-cancer-treatment-breakthrough-neuboron-medical-group-reports-success-with-first-domestic-system 2025-02-05T07:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc1f719411c8e029/novel-cldn6-targeted-therapies-show-promise-in-advanced-solid-tumors 2025-02-05T06:00:02+00:00 hourly 0.9 https://trial.medpath.com/news/f8dc6075db490160/global-survey-reveals-critical-knowledge-gaps-in-genetic-testing-for-ovarian-cancer-treatment 2025-02-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/414e0e5405a2240a/gsk-raises-2031-sales-target-to-ps40-billion-driven-by-strong-pipeline-progress 2025-02-05T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/dd9f861deb313861/diagnos-secures-2-million-in-private-placement-to-advance-ai-based-healthcare-screening-technology 2025-02-05T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9b602650d4141d2/lnp-mrna-technology-evolution-and-bioanalytical-advances-reshape-drug-delivery-landscape 2025-02-05T05:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/6200ce98b6c88efa/gsk-s-portfolio-resilience-cancer-and-hiv-gains-offset-rsv-vaccine-decline 2025-02-05T04:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/ae6d1335c558bf7f/delveinsight-report-over-50-pipeline-drugs-in-development-for-urothelial-carcinoma-treatment 2025-02-05T04:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/fa01975b3859e74b/jabil-expands-pharmaceutical-manufacturing-capabilities-with-strategic-pii-acquisition 2025-02-05T01:41:59+00:00 hourly 0.9 https://trial.medpath.com/news/b29ba1460dc0ad05/fda-greenlights-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-05T00:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/239ca0eec2bbbfd1/pathmaker-s-myoregulator-device-for-als-treatment-receives-irb-approval-for-dod-funded-clinical-trial 2025-02-05T00:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/a1d7884a22ad04fb/divergent-clinical-evidence-submissions-revealed-in-fda-and-ema-cell-and-gene-therapy-approvals 2025-02-05T00:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/9da97981201d78c5/alzheon-to-present-phase-3-data-for-novel-apoe4-targeted-alzheimer-s-pill-in-april-2025 2025-02-05T00:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/e68ca16ab92eb8b4/libtayo-becomes-first-eu-approved-immunotherapy-for-advanced-cervical-cancer 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f952bd6ee383b47b/formycon-expands-global-reach-for-eylea-biosimilar-through-strategic-partnerships-with-teva-and-lotus-pharmaceutical 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/75fc1ccaf8ef6c84/oct-analysis-reveals-key-predictors-of-visual-recovery-in-macula-off-retinal-detachment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7a6592f3ba702e02/alberta-innovates-awards-600k-grant-to-voyageur-pharmaceuticals-for-advanced-barium-contrast-media-research 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8f55046af1b5030c/groundbreaking-t-cell-therapy-leads-to-complete-remission-in-stage-4-breast-cancer-patient 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5edac183ea4debf1/priority-health-enhances-healthcare-navigation-platform-with-extended-support-services 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5f1ce796b87edf04/biogen-withdraws-aduhelm-eu-application-following-regulatory-setback 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/24de887249d53653/phase-iib-adagio-trial-adavosertib-shows-limited-efficacy-with-high-toxicity-in-uterine-serous-carcinoma 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/56bca920747719b7/ai-assisted-physicians-show-enhanced-clinical-decision-making-in-landmark-study 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/af25e95af3e5c068/astellas-discontinues-dmd-gene-therapy-programs-takes-170m-impairment-charge 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb49307792cb9c32/ai-algorithm-successfully-predicts-cancer-outcomes-using-clinical-notes-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c4afe562a746746/long-term-evolocumab-shows-strong-benefits-for-elderly-ascvd-patients-in-fourier-trial-analysis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/66acc1d565e183a7/quality-of-life-comparable-between-erleada-combinations-in-advanced-prostate-cancer-treatment 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a56ad71785695ba8/coa-unveils-comprehensive-healthcare-reform-plan-to-address-cancer-care-crisis 2025-02-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ffe5d9524ce2efc7/major-pipeline-expansion-in-schizophrenia-treatment-55-companies-developing-60-novel-therapies 2025-02-04T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/7bea5b24fe244aac/emyria-reports-significant-mdma-assisted-therapy-benefits-for-ptsd-in-clinical-trial 2025-02-04T23:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/c05b3bb11b50c380/fda-places-clinical-hold-on-amgen-s-novel-obesity-drug-candidate-amg-513 2025-02-04T22:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/776d664a42b29250/fda-reviews-pertuzumab-biosimilar-hlx11-for-her2-positive-breast-cancer-treatment 2025-02-04T22:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/15c7eddc8a15ec26/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-exposure-and-long-covid-treatment 2025-02-04T21:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/4b4f1e89e551690a/phase-3-clinical-trials-showcase-growing-promise-of-radiopharmaceutical-cancer-therapy 2025-02-04T21:22:37+00:00 hourly 0.9 https://trial.medpath.com/news/e6a9ff6f3f800458/nanoscope-to-present-126-week-vision-restoration-data-for-mco-010-gene-therapy-in-retinitis-pigmentosa 2025-02-04T21:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce5515e8f7318320/iit-guwahati-pioneers-adaptive-clinical-trial-method-for-personalized-medicine 2025-02-04T20:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/950d399f584abac4/fda-approves-first-clinical-trials-for-pig-to-human-kidney-transplants 2025-02-04T20:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/2bc68ffb61716fba/next-gen-ozempic-combo-drug-cagrisema-shows-22-7-weight-loss-with-mixed-patient-experiences 2025-02-04T20:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/6ec7b7407c2ad63f/brolucizumab-shows-promising-one-year-results-in-wet-amd-treatment-regardless-of-prior-therapy 2025-02-04T19:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/38d1e5599470e641/trilink-and-aldevron-partner-to-expand-access-to-cleancap-r-mrna-technology-for-therapeutic-development 2025-02-04T16:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbf5fd71cf6d91e4/zoetis-updates-librela-label-following-reports-of-severe-side-effects-in-dogs 2025-02-04T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/a2b2e2b0f88be0dd/world-cancer-day-2025-launches-united-by-unique-campaign-as-nccn-patient-advocates-share-personal-journeys 2025-02-04T15:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/4a84ca9df23bfc32/phasev-and-alimentiv-partner-to-revolutionize-gi-clinical-trials-through-adaptive-design-technology 2025-02-04T15:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/1f26c9752fc2ae30/clinical-trial-shows-bacopa-supplement-may-enhance-memory-and-cognitive-function 2025-02-04T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/cae81ad2e09f010a/sparx3-trial-investigates-high-intensity-exercise-s-impact-on-early-stage-parkinson-s-progression 2025-02-04T15:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/7aa0802ca8bb307a/landmark-prevention-trial-launches-to-stop-alzheimer-s-before-symptoms-begin-in-young-adults 2025-02-04T15:02:40+00:00 hourly 0.9 https://trial.medpath.com/news/efe3e72e76e106ef/resmed-expert-dr-alison-wimms-joins-incannex-s-osa-clinical-advisory-board-for-ihl-42x-development 2025-02-04T14:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/7a8c3ab9d398700b/global-hyperthyroidism-clinical-trials-landscape-analysis-reveals-key-research-trends-in-2024 2025-02-04T14:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/24257811ff127c83/therasyn-bio-and-rubix-ls-launch-joint-venture-to-develop-novel-topical-breast-cancer-therapy 2025-02-04T14:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/599388850fa8d571/shionogi-launches-first-human-trial-of-zatolmilast-for-jordan-s-syndrome-treatment 2025-02-04T13:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/ffe7121810e46e4a/multiple-hospitalizations-and-disease-duration-emerge-as-major-risk-factors-for-gallstones-in-crohn-s-disease 2025-02-04T13:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/527ea58539f97637/yale-researchers-launch-novel-app-based-intervention-to-combat-hiv-risk-in-chemsex-communities 2025-02-04T13:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/7590f215f6537583/neumora-s-depression-drug-navacaprant-fails-phase-iii-trial-triggering-stock-plunge-and-legal-investigation 2025-02-04T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9baf5e94f6162945/redhill-and-bayer-launch-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-02-04T12:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/c067cf70aea9d228/fda-clears-auron-therapeutics-novel-kat2a-b-degrader-autx-703-for-clinical-trials-in-blood-cancers 2025-02-04T12:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/47ffca9b7aaa2eb5/university-of-birmingham-pioneers-personalized-cancer-treatment-approaches-with-novel-diagnostics-and-mrna-vaccines 2025-02-04T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/258ef32829dc239e/novel-herbal-amino-acid-supplement-shows-promising-results-in-osteoarthritis-treatment 2025-02-04T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/bc984e2dfe6f3d2a/dr-agarwal-s-healthcare-makes-stock-market-debut-with-muted-expectations-following-ipo 2025-02-04T11:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/b101309317e89d1d/alys-pharmaceuticals-advances-first-genetic-medicine-for-dermatology-with-phase-2a-trial-ind-clearance 2025-02-04T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/e923cc72876b047b/rfk-jr-secures-key-senate-committee-support-after-making-vaccine-policy-commitments 2025-02-04T08:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/ef157b4b8660cf26/prior-cancer-history-associated-with-better-survival-in-metastatic-colorectal-cancer-patients-study-finds 2025-02-04T08:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/b4eee2ca4421f07c/uganda-launches-groundbreaking-first-ever-ebola-sudan-vaccine-trial-with-who 2025-02-04T06:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe8b705d4068b6c4/weight-cycling-in-type-1-diabetes-linked-to-increased-risk-of-kidney-disease-progression 2025-02-04T06:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/a24bfbf3ceb91e8e/pyxis-oncology-expands-pyx-201-clinical-program-with-new-combination-trial-and-monotherapy-cohorts 2025-02-04T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/f6cdf42b9479603b/flagship-backed-omega-therapeutics-files-for-bankruptcy-halts-cancer-drug-development 2025-02-04T04:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e514ee5c1359e10/merck-halts-gardasil-shipments-to-china-amid-demand-slump-abandons-11b-sales-target 2025-02-04T04:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/131a86593c70761c/phase-i-trial-validates-safety-of-sabr-for-extended-polymetastatic-cancer-treatment 2025-02-04T02:53:56+00:00 hourly 0.9 https://trial.medpath.com/news/dc9875184976852e/quantum-biopharma-s-unbuzzdtm-shows-40-faster-alcohol-metabolism-in-clinical-trial 2025-02-04T02:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/1740c7e71440a3bc/valerio-therapeutics-halts-clinical-trials-pivots-to-early-stage-drug-development 2025-02-04T01:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f3acad61808846e/wolfe-research-initiates-coverage-on-vera-therapeutics-with-bullish-outlook-on-iga-nephropathy-treatment 2025-02-04T01:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/970b1dfc9413587b/axtria-launches-ai-powered-platform-to-revolutionize-clinical-study-report-generation 2025-02-04T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8134e9cf6bfb2a92/seagen-secures-2-6b-deal-with-remegen-for-novel-her2-targeting-cancer-drug 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4e35b400e51bbd2/significant-weight-gain-underreported-in-alk-lung-cancer-patients-on-alecensa-treatment 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2119f7cb2c21f468/sumitomo-s-novel-schizophrenia-drug-ulotaront-fails-to-meet-primary-endpoint-in-phase-3-trials 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/84161583dde0a09b/sanofi-halts-phase-3-fitusiran-trials-due-to-new-safety-concerns-in-hemophilia-studies 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec28b64e77ce0eec/nintedanib-shows-sustained-efficacy-in-slowing-lung-function-decline-in-ssc-ild-patients-over-four-years 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc472b4f4bfca0c9/walking-program-shows-gender-specific-cognitive-benefits-in-older-adults-with-mci 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/01879864b809fd35/verily-and-sosei-heptares-achieve-early-success-in-ai-powered-gpcr-drug-discovery-for-autoimmune-diseases 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5499daa3aae0332/gene-therapy-shows-promise-in-bcg-unresponsive-bladder-cancer-treatment 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/af9910f77486dc96/world-cancer-day-highlights-critical-need-to-address-oncology-care-disparities 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2fd12f0832e442b4/lixisenatide-shows-promise-in-slowing-parkinson-s-disease-progression-in-phase-2-trial 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aca14a8dc0cfc741/mindfulness-program-shows-67-reduction-in-opioid-cravings-in-clinical-trial 2025-02-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a04c1ff1d757546/dostarlimab-achieves-100-remission-in-small-scale-colorectal-cancer-trial 2025-02-03T23:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/9afa0c5497479a56/anterogen-s-stem-cell-therapy-allo-asc-sheet-fails-to-meet-primary-endpoint-in-us-phase-2-dfu-trial 2025-02-03T23:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/4310cc5dc299d01b/oral-ketamine-shows-promise-in-reducing-ptsd-symptoms-with-fewer-side-effects 2025-02-03T22:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/e851d53404053be5/fda-greenlights-first-in-human-trial-of-novel-alopecia-treatment-hcw9302 2025-02-03T22:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/f2b49c29007be6a6/penn-state-launches-landmark-semaglutide-trial-for-outpatient-opioid-use-disorder-treatment 2025-02-03T22:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/d5b9e762a55ed1eb/t-dxd-shows-promise-in-her2-ultra-low-breast-cancer-expanding-treatment-horizons 2025-02-03T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9f97b13c342da970/median-technologies-ai-powered-lung-cancer-screening-software-achieves-clinical-trial-success 2025-02-03T19:30:29+00:00 hourly 0.9 https://trial.medpath.com/news/03b34d79e1d53208/bevacizumab-plus-pembrolizumab-shows-promise-in-platinum-resistant-nasopharyngeal-cancer 2025-02-03T18:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/0701b3bf72ff27b9/mayo-clinic-revolutionizes-clinical-trials-with-successful-home-based-research-program 2025-02-03T17:41:49+00:00 hourly 0.9 https://trial.medpath.com/news/4285c6f8cadb0ea5/vanda-acquires-global-rights-to-imsidolimab-for-gpp-in-50-million-deal-with-anaptysbio 2025-02-03T17:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/e4734a18629be100/gh-research-s-inhaled-5-meo-dmt-shows-strong-efficacy-in-phase-iib-depression-trial 2025-02-03T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/44efde493c2e0294/surmodics-pounce-xl-thrombectomy-system-shows-promise-in-first-clinical-case 2025-02-03T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/725992c02c241371/next-generation-cancer-therapies-advances-in-checkpoint-inhibitors-and-personalized-treatment 2025-02-03T15:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/be1c25fb1dcf416b/promising-results-emerge-from-dual-studies-of-blinatumomab-ponatinib-combination-in-acute-lymphoblastic-leukemia 2025-02-03T15:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/89718c962e43a677/novel-pva-enhanced-boron-drug-shows-promise-in-advancing-cancer-treatment 2025-02-03T15:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/c5c841ab7e356cca/d-d-pharmatech-completes-enrollment-for-phase-2-mash-trial-of-novel-dual-glp-1-glucagon-agonist-dd01 2025-02-03T14:59:02+00:00 hourly 0.9 https://trial.medpath.com/news/88dff7833819df99/first-welsh-patient-receives-personalized-mrna-cancer-vaccine-in-groundbreaking-trial 2025-02-03T14:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ccb21ba834f6d98/jupiter-neurosciences-teams-with-catalent-to-manufacture-jotrol-for-parkinson-s-disease-trial 2025-02-03T14:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9319926a9d3ec6d/exxel-pharma-s-ex937-advances-to-first-human-trials-for-refractory-chronic-cough-treatment 2025-02-03T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/e014bbd4bd04c7f5/acp-issues-new-treatment-guidelines-for-episodic-migraine-management 2025-02-03T14:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/2e0a34914b2c775a/study-reveals-strong-link-between-cardiovascular-disease-and-advanced-breast-cancer-risk 2025-02-03T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4fef35770a0acce6/ngs-guided-treatment-strategy-shows-promise-for-stk11-keap1-mutated-nsclc-patients 2025-02-03T13:59:33+00:00 hourly 0.9 https://trial.medpath.com/news/519f8331ac8b312a/novel-topical-drug-delivery-systems-show-promise-in-revolutionizing-breast-cancer-treatment 2025-02-03T13:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/fc5c11590f5987dd/fda-lifts-clinical-hold-on-seclidemstat-trial-43-response-rate-observed-in-advanced-blood-cancer-study 2025-02-03T13:23:39+00:00 hourly 0.9 https://trial.medpath.com/news/7638e89629059ff6/seastar-medical-secures-6m-funding-to-advance-novel-extracorporeal-inflammation-therapies 2025-02-03T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/73841bce5eed0116/paradigm-partners-with-advanced-clinical-for-pivotal-phase-iii-osteoarthritis-trial 2025-02-03T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6e463e84905e44a/mhra-launches-public-consultation-for-personalized-mrna-cancer-vaccine-regulations 2025-02-03T12:25:54+00:00 hourly 0.9 https://trial.medpath.com/news/d8d34ac28a569cef/uniqure-advances-phase-i-iia-gene-therapy-trial-for-fabry-disease-following-safety-milestone 2025-02-03T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/895b8c64cb4f5e8b/invivyd-reports-promising-phase-1-2-results-for-novel-covid-19-antibody-vyd2311 2025-02-03T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/c58670c22b68d263/fda-clears-united-therapeutics-xenotransplant-kidney-ind-clinical-trials-set-for-2025 2025-02-03T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ffe44872c76f70d/gh-research-s-novel-psychedelic-shows-promising-results-in-treatment-resistant-depression-trial 2025-02-03T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/176aab4a9cf99f1f/entrada-therapeutics-receives-uk-approval-to-begin-phase-1-2-trial-in-duchenne-muscular-dystrophy 2025-02-03T12:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/57d10264c933e060/amicus-therapeutics-to-present-extensive-research-on-fabry-and-pompe-diseases-at-worldsymposium-2025 2025-02-03T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/d370e0395fe0cded/health-disparities-in-hiv-care-new-study-reveals-critical-gaps-and-strategies-for-improving-access 2025-02-03T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/b8d9404662668b76/protalix-s-prx-115-shows-promise-in-phase-i-gout-trial-with-extended-dosing-potential 2025-02-03T09:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/2aaea099e36e398b/moderna-emerges-as-uk-s-leading-clinical-trial-sponsor-with-new-oxford-innovation-center-nearing-completion 2025-02-03T09:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/63cc67b0e673bf18/pharma-industry-maintains-commitment-to-clinical-trial-diversity-despite-political-headwinds 2025-02-03T09:00:26+00:00 hourly 0.9 https://trial.medpath.com/news/89f8f0f9b85ee429/aplagon-secures-eur7m-funding-to-advance-novel-thrombo-inflammatory-treatment-into-phase-2a-trials 2025-02-03T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/76c44da4e5c0725c/tenaya-therapeutics-secures-8m-cirm-grant-to-advance-gene-therapy-trial-for-rare-heart-condition 2025-02-03T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/a7862874033b4671/nk-cell-therapy-vcb-1102-advances-to-clinical-trial-for-advanced-pancreatic-cancer-treatment 2025-02-03T07:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/f26856fdd146cd2b/nona-biosciences-expands-reach-with-strategic-partnerships-in-animal-health-and-breast-cancer-therapeutics 2025-02-03T07:43:26+00:00 hourly 0.9 https://trial.medpath.com/news/b77ee6186d44fec2/celltrion-advances-novel-adc-cancer-drug-ct-p70-with-fda-ind-filing 2025-02-03T07:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/ad43f372b1053200/early-stage-snakebite-drug-varespladib-shows-promise-for-pre-hospital-treatment-despite-trial-setback 2025-02-03T07:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/618fc24a17cb4eae/lancet-commission-charts-global-roadmap-to-transform-breast-cancer-care-and-address-health-inequities 2025-02-03T07:00:56+00:00 hourly 0.9 https://trial.medpath.com/news/fb923e6820e373f4/advancell-secures-112m-in-oversubscribed-series-c-to-advance-radiopharmaceutical-cancer-therapies 2025-02-03T06:45:25+00:00 hourly 0.9 https://trial.medpath.com/news/1cb5ca3ab8b59eed/pmwc-2025-to-address-key-challenges-in-pharmacogenomics-implementation-and-access 2025-02-03T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/697baa95a93c9f8c/kenox-and-lactiga-partner-to-develop-first-in-class-mucosal-immunotherapy-for-immunodeficient-patients 2025-02-03T06:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/7f0928f24e27004b/radiopharmaceuticals-reshape-cancer-treatment-landscape-from-thyroid-to-advanced-prostate-cancer 2025-02-03T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ca211b6a376bbf5/record-breaking-year-for-rare-disease-clinical-trials-as-2021-marks-peak-in-research-activity 2025-02-03T05:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/d8ff07d1c676c972/rakuten-launches-global-phase-iii-trial-of-novel-photoimmunotherapy-for-head-and-neck-cancer 2025-02-03T04:44:44+00:00 hourly 0.9 https://trial.medpath.com/news/b7dce9c8c1bed868/gedatolisib-shows-promising-77-month-overall-survival-in-advanced-breast-cancer-phase-1b-trial 2025-02-03T04:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/70be1d964244e8b7/thc-shows-promise-in-managing-agitation-in-alzheimer-s-disease-ctad-trial-reports 2025-02-03T04:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/4e5e1acd1d2de15c/ose-immunotherapeutics-advances-global-phase-3-trial-for-cancer-vaccine-tedopi 2025-02-03T04:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/ddfab82bf4f5437f/novel-btk-bcl2-inhibitor-combination-shows-promise-against-drug-resistant-dlbcl-with-bcl10-mutations 2025-02-03T04:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/eb839b1ceba5e142/sanofi-s-amlitelimab-advances-to-long-term-safety-study-for-atopic-dermatitis-treatment-in-india 2025-02-03T04:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/3124ba58775c090a/iran-reports-19-7-growth-in-pharmaceutical-exports-advances-in-cell-and-gene-therapy 2025-02-03T04:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/6111d65b3038b18a/digoxin-shows-cost-effectiveness-over-beta-blockers-in-heart-failure-treatment-uk-study-finds 2025-02-03T01:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/7b2d1a926eb60e1b/biontech-s-bnt111-cancer-vaccine-shows-promise-in-advanced-melanoma-phase-2-trial 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/47402086b4e9ba3d/immunocore-advances-clinical-pipeline-with-multiple-phase-3-trials-and-new-drug-candidates 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/856b670221f6cbdd/ucl-repair-with-internal-bracing-shows-faster-recovery-than-traditional-tommy-john-surgery 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e02bd6295ef48f54/onco-innovations-acquires-ai-pioneer-inka-health-to-transform-cancer-drug-development 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/732b235cec5c0674/ecp-treatment-shows-promising-results-for-steroid-resistant-chronic-gvhd-patients 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ca67f181e439bd3/new-clinical-trials-to-evaluate-advanced-cvad-securement-methods-in-pediatric-patients 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/55fcd26b9bffcbeb/light-trial-pioneers-new-approach-to-glaucoma-and-ocular-hypertension-management 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/98fab33c62301f4e/fda-approves-capvaxive-first-adult-specific-21-valent-pneumococcal-vaccine 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/99ee191f7247dd9b/long-acting-buprenorphine-monthly-injection-trial-launches-in-australia-for-opioid-dependence-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c900f2a20102e5d/verge-genomics-launches-first-clinical-trial-of-ai-discovered-als-drug-vrg50635 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5d9959f9e5f7b39/novel-trial-aims-to-optimize-antibiotic-duration-for-ventilator-associated-pneumonia-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/70810b050a652347/induction-chemoimmunotherapy-shows-promise-in-unresectable-stage-iii-nsclc-treatment 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/df3f4cce91382d73/precision-medicine-trial-leads-to-complete-response-in-metastatic-prostate-cancer-patient-using-targeted-immunotherapy 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d47bb7d8decc3a20/synlogic-s-novel-probiotic-therapy-shows-promise-in-phase-2-pku-trial-advancing-to-phase-3 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/54fe39787dd066af/novel-discovery-car-molecules-can-transfer-between-t-cells-in-cancer-immunotherapy 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/66495a974ef61810/major-clinical-trial-investigates-impact-of-hydration-in-end-of-life-care-chelsea-ii-study-launches-across-uk 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e311993166c88e3c/omega-3-supplementation-shows-promise-in-slowing-biological-aging-clinical-trial-reveals 2025-02-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/188609b89a7b0137/hmb-supplementation-shows-promise-in-duchenne-muscular-dystrophy-dogs-improving-activity-and-protein-metabolism 2025-02-02T20:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/7e510d13be59154c/pegmolesatide-shows-promise-as-long-acting-anemia-treatment-in-phase-ii-trials-for-ckd-patients 2025-02-02T17:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/b80603294c34afcb/novel-ecg-feature-analysis-reveals-p-wave-changes-as-early-warning-sign-for-atrial-fibrillation 2025-02-02T15:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/f2426a006b78002f/novel-blood-test-trial-in-uk-promises-earlier-more-accessible-dementia-diagnosis 2025-02-02T15:03:05+00:00 hourly 0.9 https://trial.medpath.com/news/0fd958f2868bba1e/fitusiran-shows-promising-results-in-phase-3-trials-for-hemophilia-treatment 2025-02-02T15:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/31fe3ce1d14433de/who-deploys-2160-experimental-sudan-ebolavirus-vaccine-doses-in-uganda-amid-new-outbreak-concerns 2025-02-02T15:02:21+00:00 hourly 0.9 https://trial.medpath.com/news/e7df3164e78495a2/mobile-vision-pod-innovation-accelerates-corneal-disease-clinical-trial-progress 2025-02-02T15:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/a61d1627c3b049ac/novel-statistical-method-enhances-treatment-effect-analysis-in-follicular-lymphoma-study 2025-02-02T15:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/99e4513a04d9990d/early-exclusive-enteral-feeding-shows-promising-results-in-preterm-infants-clinical-trial-findings 2025-02-02T12:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/a9d955ada2cceae1/breakthrough-developments-in-dermatology-psoriasis-alopecia-and-atopic-dermatitis-treatment-advances 2025-02-02T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/79709bd5072c9653/amgen-s-maritide-weight-loss-drug-shows-promise-despite-market-skepticism 2025-02-02T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ef7142d41d58928/novel-dual-irak4-flt3-inhibitor-emavusertib-shows-promise-in-mds-and-aml-treatment 2025-02-02T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d908d602f7b5f7c1/ayurvedic-supplement-body-revival-shows-promise-in-phase-ii-breast-cancer-trial 2025-02-02T03:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/8224ebeac67da784/global-health-crisis-unfolds-as-foreign-aid-pause-disrupts-critical-medical-programs 2025-02-02T00:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/18af6a0c0a59d472/alexion-launches-phase-3-trial-of-ultomiris-for-severe-covid-19-pneumonia 2025-02-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4b391858e286361e/eu-approves-beyfortus-first-single-dose-rsv-prevention-for-infants 2025-02-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/31677aa2f2b4a044/nigeria-advances-lassa-fever-vaccine-development-with-250m-cepi-investment-and-multi-country-trials 2025-02-01T22:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/451009603c05f54b/annexon-s-gbs-drug-trial-data-readout-imminent-stock-surges-50-after-hours 2025-02-01T20:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/7862e33cba55ea02/india-eliminates-import-duties-on-36-life-saving-drugs-for-cancer-and-rare-diseases 2025-02-01T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/c0420ade7f474c9b/expert-insights-managing-egfr-mutated-nsclc-with-brain-metastases-lessons-from-clinical-practice 2025-02-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/cf685ef9c12f4a37/novel-immunotherapy-combinations-show-promise-beyond-pd-1-inhibition-in-advanced-nsclc 2025-02-01T16:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/cd2775a1e1c66cfb/novel-radiotherapy-approaches-show-promise-in-limited-stage-small-cell-lung-cancer-treatment 2025-02-01T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/e58056790f4398d4/biomarker-expression-levels-show-variable-correlation-with-adc-efficacy-in-ovarian-cancer-treatment 2025-02-01T12:53:54+00:00 hourly 0.9 https://trial.medpath.com/news/364d0a296224a43d/quality-of-life-measures-gain-critical-importance-in-gynecologic-oncology-care 2025-02-01T12:53:31+00:00 hourly 0.9 https://trial.medpath.com/news/6e0431941b446337/aga-updates-guidelines-for-hepatitis-b-reactivation-prevention-with-risk-stratified-approach 2025-02-01T09:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/d367c6a802fe53eb/nih-launches-phase-2-trial-of-novel-dengue-treatment-av-1-amid-rising-us-cases 2025-02-01T07:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/540698a6f2f25b1f/novel-3d-printed-mouthguard-device-enters-clinical-trial-for-sleep-apnea-treatment 2025-02-01T04:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/695c101baea1d28d/novel-peptide-compounds-promise-weight-loss-benefits-without-ozempic-s-gi-side-effects 2025-02-01T02:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/9decf659d4d27b85/uci-researchers-launch-innovative-phase-2-trial-for-advanced-gastric-cancer-treatment 2025-02-01T02:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/36c2c2445739ab60/fda-approves-ozempic-for-chronic-kidney-disease-in-type-2-diabetes-patients 2025-02-01T02:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/e8d66648335c9745/nice-approves-groundbreaking-crispr-gene-therapy-for-severe-sickle-cell-disease-in-england 2025-02-01T02:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/485c00d66c44b9fb/ema-recommends-eight-new-medicines-including-cancer-therapies-and-vaccines-for-eu-approval 2025-02-01T02:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/d934133a73379e85/merck-s-capvaxive-receives-positive-chmp-opinion-for-adult-pneumococcal-disease-prevention-in-eu 2025-02-01T02:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/784b9d937b0b580c/chou2-pharma-initiates-pharmacokinetic-study-for-novel-canine-epilepsy-treatment 2025-02-01T02:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/fc93332d4f473ae8/ab-science-launches-new-phase-3-trial-of-masitinib-for-als-with-enhanced-protocol 2025-02-01T02:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/9c6b4be3fdcb8a38/novel-group-therapy-shows-promise-in-treating-mental-health-self-stigma-italian-clinical-trial-launches 2025-02-01T02:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/13c1d154f61cb289/immutep-reports-strong-financial-position-with-a-159m-cash-balance-advances-clinical-programs 2025-02-01T02:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/8d1546f6d63076e8/advancements-in-early-detection-of-treatment-responsive-rapidly-progressive-dementia 2025-02-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe484e7dae350ee3/enzyvant-s-rvt-802-receives-landmark-dual-fast-track-status-from-fda-for-complete-digeorge-syndrome 2025-01-31T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/509024137f694f3a/bluebird-bio-s-zynteglo-secures-historic-eu-approval-for-beta-thalassemia-gene-therapy 2025-01-31T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/ea4d29420a6381b0/novel-approaches-reshape-lymphoma-treatment-landscape-bispecific-antibodies-and-mrd-guided-therapy-show-promise 2025-01-31T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d64b095f766b35d/cardinal-health-launches-navista-alliance-to-strengthen-independent-community-oncology-practices 2025-01-31T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/229cc134808784e0/novartis-pushes-back-phase-3-data-timeline-for-ionis-partnered-cardiac-therapy 2025-01-31T19:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/287b653f70125c3c/fresh-embryo-transfer-shows-superior-results-for-low-prognosis-ivf-patients-chinese-study-finds 2025-01-31T16:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/6ba3cd8db184aeee/ctdna-analysis-shows-promise-in-monitoring-daraxonrasib-treatment-response-in-pancreatic-cancer 2025-01-31T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/2af5c9d75b68ddf9/livmarli-shows-long-term-efficacy-in-relieving-itch-for-adolescents-with-alagille-syndrome 2025-01-31T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/52b4011e3a88080c/galderma-s-relabotulinumtoxina-shows-sustained-6-month-efficacy-in-phase-iiib-trial-for-frown-lines 2025-01-31T16:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/d038219a3c3687df/phase-3-tropion-lung12-trial-launches-to-evaluate-datroway-for-early-stage-lung-cancer 2025-01-31T16:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/cc15fdcc21a2090c/hypofractionated-partial-breast-irradiation-shows-promising-results-in-early-stage-breast-cancer-trial 2025-01-31T16:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/8562f7335321ef49/ai-powered-platform-revolutionizes-cancer-treatment-personalization-through-multi-modal-data-analysis 2025-01-31T16:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/17e88916cbd5b7b5/cedars-sinai-partners-with-oxford-science-enterprises-to-advance-digital-health-innovation-invests-2m-in-ai-powered-neurology-platform 2025-01-31T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/a377b01151161599/fr-alpha-and-b7-h4-expression-found-in-over-80-of-endometrial-cancer-cases-supporting-adc-development 2025-01-31T16:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/bcfefd3796089a8a/next-generation-adcs-show-promise-in-advancing-ovarian-cancer-treatment-options 2025-01-31T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/683171def115b310/fda-grants-ind-clearance-to-gameto-s-novel-ivf-treatment-fertilo-paving-way-for-phase-3-trials 2025-01-31T13:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/f526519c98f06f91/fda-approves-celltrion-s-avtozma-a-new-tocilizumab-biosimilar-for-multiple-inflammatory-conditions 2025-01-31T13:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/1c78bc7e0ef4664f/takeda-discontinues-soticlestat-development-after-failed-phase-iii-epilepsy-trials 2025-01-31T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/14b838e790c6a174/united-health-products-advances-fda-application-for-novel-hemostatic-agent-cellustat 2025-01-31T13:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/b17618cc4ddab3a7/private-equity-hospital-acquisitions-lead-to-declining-patient-care-experience-jama-study-finds 2025-01-31T12:40:35+00:00 hourly 0.9 https://trial.medpath.com/news/0560e33e33a1a432/university-of-calgary-launches-validation-study-for-advanced-at-home-hormone-monitoring-device 2025-01-31T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5305601f3d3fcc6/ppp2r1a-mutations-linked-to-better-survival-in-high-risk-endometrial-cancer-patients-on-immunotherapy 2025-01-31T12:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/a08882e96e83a339/study-reveals-increased-recovery-risks-for-elderly-and-frail-patients-after-major-gynecologic-cancer-surgery 2025-01-31T11:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/f3b79c5bd62d9645/mind-medicine-s-mm120-advances-to-phase-3-trials-following-strong-anxiety-treatment-results 2025-01-31T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c9670ff6f758087/rfk-jr-s-hhs-secretary-confirmation-hearings-reveal-concerning-stance-on-vaccines-and-healthcare-policy 2025-01-31T10:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/c84279f1cd664508/germany-overhauls-drug-pricing-system-introduces-confidential-pricing-eliminates-international-reference-pricing 2025-01-31T09:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/e4d8c8c0b4027f9b/supreme-court-to-review-aca-s-no-cost-prep-coverage-mandate-access-to-preventive-care-at-stake 2025-01-31T09:25:46+00:00 hourly 0.9 https://trial.medpath.com/news/5789d0b880688613/novartis-extends-timeline-for-pelacarsen-phase-3-cardiovascular-trial-to-2026 2025-01-31T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/49823a30708f3fb9/masld-prevalence-in-us-adults-projected-to-rise-to-41-4-by-2050-signaling-major-health-crisis 2025-01-31T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4a6a78cbd8877208/study-reveals-different-effects-of-cll-therapies-on-blood-cell-behavior-ibrutinib-shows-promise-in-normalizing-rbc-aggregation 2025-01-31T07:58:04+00:00 hourly 0.9 https://trial.medpath.com/news/dc34257737e7f84b/ai-model-achieves-93-8-sensitivity-in-early-colorectal-cancer-detection 2025-01-31T07:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/48aae781aa40cf11/lanifibranor-shows-promise-in-metabolic-liver-disease-treatment-phase-iii-results-expected-2026 2025-01-31T07:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/f086460a3ac2c0ee/velocity-clinical-research-partners-with-vct-to-combat-double-enrollment-in-clinical-trials 2025-01-31T07:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/887cb2e5c65257cc/clinical-decision-support-tool-enhancement-significantly-improves-cancer-biomarker-documentation 2025-01-31T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/be4edf530c8bc714/experts-to-explore-cell-and-gene-therapy-frontiers-in-rare-disease-treatment-at-upcoming-webinar 2025-01-31T03:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/5b2d357c8bb76b3a/cargo-therapeutics-halts-phase-2-firce-1-trial-of-firi-cel-for-large-b-cell-lymphoma-due-to-safety-concerns 2025-01-31T02:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/83fe3639277974b9/ai-healthcare-startups-secure-major-funding-rad-ai-leads-with-60m-series-c-round 2025-01-31T02:00:24+00:00 hourly 0.9 https://trial.medpath.com/news/29553ed74830d418/study-shows-no-added-benefit-of-combining-chemotherapy-with-pd-1-inhibitors-in-second-line-nsclc-treatment 2025-01-31T00:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/d9bb8b039e9cba48/dostarlimab-shows-promise-in-neoadjuvant-treatment-of-dmmr-colorectal-cancer-asco-2024-update 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/da35a5a14fb4aeac/cancer-monoclonal-antibody-partnerships-surge-with-599-deals-recorded-since-2016 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/795429c526eca8d6/pulsesight-therapeutics-initiates-clinical-development-of-novel-transferrin-therapy-for-geographic-atrophy 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ecb4b3fb757a0eac/bayer-expands-clinical-trial-portfolio-with-studies-on-sepsis-coagulopathy-and-obstructive-sleep-apnea 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4b8b58aeef332d84/astrazeneca-s-oral-drug-danicopan-receives-chmp-backing-for-pnh-related-anaemia-treatment 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d1f8f6bd87fcf910/tensive-secures-eur14m-series-a-funding-for-novel-bio-absorbable-breast-implant-development 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7f2d2e79259137f/ucla-secures-5-8m-cirm-grant-for-pioneering-angelman-syndrome-gene-therapy-research 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f257d5dc8c19ca63/novel-molecular-classification-system-for-retroperitoneal-liposarcoma-reveals-two-distinct-prognostic-subtypes 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b2fa67a9ccf913a2/barda-awards-24m-to-advance-crispr-engineered-phage-therapy-for-drug-resistant-utis 2025-01-31T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0562ed65426d95eb/cargo-therapeutics-firi-cel-phase-2-trial-falls-short-leading-to-major-stock-downgrade 2025-01-30T23:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/13c84a997a6aec6d/mobile-vision-clinics-enable-successful-rare-eye-disease-trial-enrollment-during-pandemic 2025-01-30T22:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/7e07138ee45ab495/koru-medical-partners-on-phase-iii-trial-for-rare-renal-disorder-drug-delivery 2025-01-30T22:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/8c8a5b6764a8653a/fda-approves-symbravo-novel-dual-action-treatment-for-acute-migraine 2025-01-30T22:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/4c233c7e9c540ffe/hookipa-completes-enrollment-in-phase-1b-trial-of-hiv-therapeutic-vaccine-hb-500 2025-01-30T22:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/71fb1db03f6ec1d2/pipeline-for-chronic-pain-treatment-expands-with-25-drug-candidates-under-development 2025-01-30T22:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/e4951d373f29a50d/internet-based-cbt-shows-promise-in-treating-ocd-during-covid-19-pandemic 2025-01-30T22:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/f8b5302ae59b14ca/kazia-therapeutics-launches-groundbreaking-trial-combining-paxalisib-with-immunotherapy-for-triple-negative-breast-cancer 2025-01-30T22:01:24+00:00 hourly 0.9 https://trial.medpath.com/news/6c1c060867d99893/cargo-therapeutics-halts-phase-2-lbcl-trial-due-to-safety-concerns-cuts-workforce-by-50 2025-01-30T21:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/515fdf44ea92e840/kazia-therapeutics-initiates-novel-phase-1b-trial-combining-paxalisib-with-immunotherapy-for-advanced-breast-cancer 2025-01-30T21:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/da401717f7bf5bb6/hhs-approves-mandatory-fentanyl-testing-for-truck-drivers-starting-july-2024 2025-01-30T21:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/6048ef9f64ffa75e/olutasidenib-plus-azacitidine-shows-promise-in-idh1-mutated-relapsed-refractory-aml 2025-01-30T18:46:06+00:00 hourly 0.9 https://trial.medpath.com/news/9e954539b4f3417e/blinklab-initiates-major-fda-registration-study-for-autism-diagnostic-platform 2025-01-30T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3ee9f9ba8e83ed3b/novel-mouse-model-and-organoid-program-advance-drug-discovery-for-adult-granulosa-cell-tumors 2025-01-30T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/6279959e9eaacace/affluent-medical-s-artus-urinary-sphincter-advances-to-female-clinical-trials-following-successful-male-study 2025-01-30T17:45:06+00:00 hourly 0.9 https://trial.medpath.com/news/a076a6cb04910972/ethris-s-inhaled-mrna-therapy-shows-promise-in-phase-1-asthma-trial 2025-01-30T17:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/535db125e4ed37ad/phase-2-trial-shows-promise-serplulimab-hlx04-combination-safe-for-advanced-liver-cancer 2025-01-30T16:56:44+00:00 hourly 0.9 https://trial.medpath.com/news/a216f562a9217033/immunitybio-and-beigene-launch-phase-iii-trial-combining-tislelizumab-and-anktiva-for-advanced-nsclc 2025-01-30T16:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/d699685e626b6367/peace-3-trial-investigates-enzalutamide-radium-223-combination-for-metastatic-prostate-cancer 2025-01-30T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/321f3e612fdb1ac9/collision-trial-thermal-ablation-proves-noninferior-to-surgery-for-colorectal-liver-metastases 2025-01-30T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/a4b9979346030460/avecho-biotechnology-advances-phase-iii-cbd-insomnia-trial-despite-initial-recruitment-challenges 2025-01-30T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/fe1e10a237b1722e/machine-learning-tool-enhances-genetic-testing-decisions-in-nicu-improving-patient-care-efficiency 2025-01-30T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/80597cd9c3bc550c/uniqure-s-sod1-als-gene-therapy-amt-162-advances-to-next-dosing-phase-after-positive-safety-review 2025-01-30T16:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/7c1dd6b81a387be1/zipalertinib-shows-promising-results-in-phase-2b-nsclc-trial-cullinan-management-plans-regulatory-filing 2025-01-30T16:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/010d6da5a9a30291/novel-nasal-delivery-of-amifostine-shows-promise-in-advancing-pancreatic-cancer-radiation-therapy 2025-01-30T16:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/e5a92419f3c334f2/ironwood-pharmaceuticals-cuts-50-of-workforce-amid-lower-revenue-projections-focuses-on-apraglutide-development 2025-01-30T15:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/41781604f63ad3f1/anetumab-ravtansine-plus-bevacizumab-falls-short-against-standard-therapy-in-ovarian-cancer-trial 2025-01-30T15:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/63584d23490aaaae/nice-approves-novel-sublingual-tablet-for-severe-dust-mite-allergy-treatment-on-nhs 2025-01-30T14:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/81c9a03c3405d088/molecular-subtypes-drive-treatment-outcomes-in-stage-iii-endometrial-cancer-canadian-study-shows 2025-01-30T14:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/69353a2c8eb6db4a/cargo-therapeutics-halts-phase-ii-car-t-trial-due-to-safety-concerns 2025-01-30T14:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/fa761ba68f6a6e28/shionogi-s-novel-rsv-antiviral-achieves-89-viral-load-reduction-in-phase-ii-trial 2025-01-30T14:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/aeeb034260b3970e/novel-tau-radiotracers-show-superior-performance-in-alzheimer-s-detection-compared-to-fda-approved-tauvid 2025-01-30T14:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/462daba2d40424ef/texas-oncology-executive-outlines-strategy-for-value-based-cancer-care-integration 2025-01-30T13:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/0e32dc4b76aa1fd8/novel-macrophage-based-cancer-immunotherapy-shows-promise-for-solid-tumors 2025-01-30T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/fada7332b8c33517/owkin-initiates-phase-i-trial-of-ai-optimized-triple-inhibitor-okn4395-for-solid-tumors 2025-01-30T13:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/59b6440d2651bb94/tubulis-initiates-phase-i-iia-trial-of-novel-5t4-targeting-adc-for-advanced-solid-tumors 2025-01-30T13:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/c054eba27f2c69a9/mayo-clinic-advances-eye-cancer-treatment-with-novel-drug-trial-and-organoid-research 2025-01-30T13:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/516f0ff9a31d0fd0/inhibikase-halts-parkinson-s-drug-development-following-phase-ii-trial-setback 2025-01-30T12:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/c46f09d1b150021a/imvax-raises-29m-to-advance-novel-glioblastoma-treatment-through-phase-iib-trial 2025-01-30T12:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/a4db0b51a7226d25/alterity-s-ath434-shows-promise-in-phase-2-multiple-system-atrophy-trial-analyst-raises-price-target 2025-01-30T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/544dbccbf6e46529/ethris-reports-successful-phase-1-results-for-novel-nasal-mrna-therapy-eth47-in-asthma-treatment 2025-01-30T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d8f3c8bf0356d0e3/global-rare-disease-drug-development-shows-promise-with-7000-conditions-under-focus 2025-01-30T09:42:29+00:00 hourly 0.9 https://trial.medpath.com/news/a67e375af55a3368/ai-powered-clinical-trial-simulations-promise-to-transform-drug-development-process 2025-01-30T09:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/80b3b5e80cd931e9/whole-genome-sequencing-shows-promise-in-multiple-myeloma-despite-implementation-challenges 2025-01-30T09:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/78aae0cf4b7cd7ba/study-reveals-why-children-s-cancer-immunotherapy-differs-from-adults-opening-path-to-precision-medicine 2025-01-30T09:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/c84222919e22cdc0/creative-medical-s-celz-201-ddt-shows-promising-safety-profile-in-phase-1-2-degenerative-disc-disease-trial 2025-01-30T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/43d921594c2e900e/major-ibd-summit-to-address-precision-medicine-advances-in-drug-development 2025-01-30T08:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/17d884011bad6013/genetic-study-confirms-causal-link-between-rheumatoid-arthritis-and-increased-fracture-risk 2025-01-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/b381486ca8d37711/angiodynamics-launches-ambition-btk-trial-to-evaluate-auryon-laser-system-for-critical-limb-ischemia 2025-01-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/5162783e848f81af/northstrive-biosciences-launches-preclinical-study-of-el-32-probiotic-combined-with-semaglutide-for-obesity-treatment 2025-01-30T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d399895e3e5151b/understanding-long-term-recurrence-risks-in-early-hr-her2-breast-cancer-beyond-nodal-status 2025-01-30T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3eeb213e79b463c6/regulus-advances-rgls-8429-to-phase-iii-for-polycystic-kidney-disease-following-promising-phase-ib-results 2025-01-30T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/6f62e1a9ad3129b5/endometriosis-pipeline-expands-with-20-novel-therapies-in-development-across-15-companies 2025-01-30T05:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/12d29ee22771ce34/japan-s-controversial-approval-of-tecovirimat-for-mpox-treatment-despite-failed-clinical-trials 2025-01-30T05:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/91e8159b34f93fdc/three-novel-9-month-regimens-show-promise-in-drug-resistant-tb-treatment 2025-01-30T05:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/85a670c1249c748e/oncosil-medical-expands-global-reach-with-new-distribution-deals-and-key-regulatory-milestones 2025-01-30T05:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/58aaa8e45f3d6634/60-degrees-pharmaceuticals-advances-arakoda-for-chronic-babesiosis-treatment-with-phase-ii-trial-approval 2025-01-30T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/4c87e5c66ed51149/novel-car-t-cell-therapies-show-promise-in-relapsed-multiple-myeloma-trials-at-roswell-park 2025-01-30T05:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/ee88915503a97e0d/lasofoxifene-shows-promise-in-improving-urogenital-symptoms-for-esr1-mutated-breast-cancer-patients 2025-01-30T05:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/391ef292f9f88df1/fda-grants-breakthrough-status-to-orthopreserve-s-novel-meniscus-replacement-implant 2025-01-30T03:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/54e6c2cccba36562/zipalertinib-shows-40-response-rate-in-egfr-exon-20-nsclc-meeting-phase-1-2-trial-endpoint 2025-01-30T03:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/46cc1bd72115f9ed/stem-cell-heart-patches-show-promise-in-groundbreaking-clinical-trial 2025-01-30T03:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/d2d41e79d5e67baa/zentalis-cuts-40-workforce-focuses-on-azenosertib-phase-ii-development-in-gynecological-cancers 2025-01-30T03:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/d1963868de8c3ccb/regulus-adpkd-drug-farabursen-shows-promise-in-phase-1b-trial-fda-agrees-to-single-pivotal-phase-3-study 2025-01-30T03:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/45eeb36342d4fb1e/sozinibercept-shows-promise-in-wet-amd-treatment-as-opthea-s-pivotal-trials-progress 2025-01-30T02:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/8757471e5f59afde/remedy-pharmaceuticals-to-present-pivotal-cirara-data-for-large-hemispheric-stroke-at-isc-2025 2025-01-30T01:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/f34d6513d1e37dae/kashiv-s-orencia-biosimilar-advances-to-phase-iii-following-successful-phase-i-results 2025-01-30T01:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/c4aa9d897821f188/fda-expands-ozempic-approval-for-kidney-disease-and-cardiovascular-risk-reduction 2025-01-30T01:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/d3a113358e97f24f/fda-approves-generic-everolimus-for-tuberous-sclerosis-complex-brain-tumors 2025-01-30T01:01:39+00:00 hourly 0.9 https://trial.medpath.com/news/b9d7e9f6cc349d7c/iaso-bio-s-novel-car-t-therapy-equecabtagene-autoleucel-under-review-in-singapore-for-multiple-myeloma-treatment 2025-01-30T01:01:10+00:00 hourly 0.9 https://trial.medpath.com/news/647e819325b23c7a/hvivo-expands-european-presence-with-eur10m-acquisition-of-crs-clinical-research-units 2025-01-30T00:31:16+00:00 hourly 0.9 https://trial.medpath.com/news/de449b771a0d073d/opthea-s-opt-302-eye-disease-treatment-shows-promise-as-phase-iii-trials-progress 2025-01-30T00:01:47+00:00 hourly 0.9 https://trial.medpath.com/news/b71b21c1c5985019/cargo-therapeutics-halts-car-t-development-after-safety-concerns-announces-50-staff-reduction 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5626fb1ac327551c/fda-issues-complete-response-letter-for-checkpoint-s-cosibelimab-in-advanced-skin-cancer 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca56519f369218e9/dental-flossing-associated-with-22-lower-stroke-risk-and-reduced-afib-in-25-year-study 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/701b4a59c26c6ff3/fda-approves-hemgenix-first-gene-therapy-for-hemophilia-b-at-3-5m-per-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d64f3c34ff3d17ce/pipeline-analysis-reveals-20-drug-candidates-for-c-met-nsclc-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/33fd6c8d984e9e0c/aduro-clean-technologies-patents-novel-process-design-for-plastic-recycling-technology 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d5d1f1e5f691e41d/fda-grants-emergency-use-authorization-to-lilly-s-bebtelovimab-for-covid-19-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9046aec76078b397/pipeline-analysis-reveals-75-drug-candidates-in-development-for-advanced-cervical-cancer-treatment 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b2445affaf2e6882/vaxcyte-s-31-strain-pneumococcal-vaccine-shows-superior-immune-response-over-prevnar-20-in-phase-1-2-trial 2025-01-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4cc988301e423913/fda-grants-rmat-designation-to-beacon-s-gene-therapy-for-x-linked-retinitis-pigmentosa 2025-01-29T23:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/1ac81d146644bf10/long-term-study-shows-pet-guided-treatment-success-in-early-stage-hodgkin-lymphoma 2025-01-29T23:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/ed1cba2a04b85c3e/promis-neurosciences-to-present-latest-developments-in-neurodegenerative-disease-programs-at-guggenheim-biotech-conference 2025-01-29T23:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/fe74dbb9ef5cd3ff/eli-lilly-terminates-phase-ii-volenrelaxin-trial-in-chronic-kidney-disease 2025-01-29T23:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/3d8dd555d40bdf62/propheci-trial-launches-to-test-pyrophosphate-treatment-for-rare-calcification-disorder-pxe 2025-01-29T23:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/53e2fdefbd93d7b9/global-gamma-delta-t-cell-therapy-pipeline-expands-with-over-30-cancer-treatments-in-development 2025-01-29T22:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/58eb981d4dd8c12d/study-shows-decentralized-clinical-trials-enhance-demographic-diversity-in-patient-enrollment 2025-01-29T22:01:31+00:00 hourly 0.9 https://trial.medpath.com/news/636782b01bab8cfb/study-reveals-morning-after-pill-ingredient-ulipristal-acetate-can-induce-abortions 2025-01-29T21:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/f69948b8778c8050/cardiomyopathy-market-projected-to-reach-20-billion-by-2035-as-novel-therapies-advance-through-clinical-development 2025-01-29T18:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/599cf56cfafb3be8/nice-discontinues-review-of-lenvatinib-pembrolizumab-combination-for-advanced-endometrial-cancer 2025-01-29T17:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/e1768efc6f3f60a5/next-life-sciences-secures-200k-grant-to-advance-novel-male-contraceptive-hydrogel 2025-01-29T17:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/75a53421a63026a7/regulus-therapeutics-reports-mixed-results-for-adpkd-program-shares-drop-24 2025-01-29T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/386a04695d3babbc/nih-collaboratory-launches-arbor-telehealth-trial-to-transform-rural-back-pain-care 2025-01-29T16:44:56+00:00 hourly 0.9 https://trial.medpath.com/news/7b1d9a060ee06ef2/novel-tad-sie-algorithm-shows-promise-in-optimizing-clinical-trial-sample-sizes 2025-01-29T16:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/f76ee639669e1fe0/gut-microbiota-research-in-sepsis-reveals-new-therapeutic-targets-and-biomarkers 2025-01-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/430da5ced14029ce/fda-grants-ind-approval-for-first-ever-umbilical-cord-blood-derived-allogeneic-car-t-therapy 2025-01-29T14:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/719495943df21e77/uzedy-r-exceeds-sales-expectations-with-117m-revenue-in-first-full-year 2025-01-29T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/34497569dc51e4c7/ocean-biomedical-secures-3-5m-nih-grant-to-advance-novel-malaria-vaccine-development 2025-01-29T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f0ec3995fa7f0e0/ucsf-launches-75-4m-platform-trial-to-test-multiple-psp-treatments-with-focus-on-diversity 2025-01-29T14:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/7ab4638514f3fac8/braf-status-and-response-kinetics-guide-first-line-immunotherapy-selection-in-advanced-melanoma 2025-01-29T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2cc17c6c0ed85aa8/myriad-genetics-advances-early-pregnancy-screening-with-eight-week-nipt-study-results 2025-01-29T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/48baee7823a0f640/okyo-pharma-advances-phase-2a-trial-for-first-ever-neuropathic-corneal-pain-treatment 2025-01-29T13:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/448a2b9928c0568b/fda-clears-ind-for-novel-inhaled-jak-inhibitor-frevecitinib-in-severe-asthma-treatment 2025-01-29T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/9208bd146218e432/china-s-nmpa-accepts-drug-application-for-novel-myopia-treatment-nvk002 2025-01-29T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/652260f1af676942/itm-s-novel-radiopharmaceutical-outperforms-everolimus-in-late-stage-gep-net-trial 2025-01-29T11:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/883c9e983c158200/trump-administration-commits-to-medicare-drug-price-negotiations-with-modified-approach 2025-01-29T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/82ce678199f309c7/chronic-spontaneous-urticaria-market-expected-to-reach-36-billion-by-2035-as-novel-targeted-therapies-transform-treatment-landscape 2025-01-29T10:00:27+00:00 hourly 0.9 https://trial.medpath.com/news/b9ec499b76d4361d/montefiore-einstein-cancer-center-secures-prestigious-three-year-coc-accreditation-highlighting-excellence-in-research-and-care 2025-01-29T10:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/1f53f2071cb15281/fda-clears-roche-s-novel-lipoprotein-a-blood-test-with-molar-unit-measurement 2025-01-29T09:50:44+00:00 hourly 0.9 https://trial.medpath.com/news/70e3b7a1ed8d3162/teva-pharmaceutical-reports-strong-q4-revenue-but-stock-drops-on-conservative-2025-guidance 2025-01-29T09:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/8a5081455ddf1b70/real-world-analysis-shows-extended-disease-progression-free-time-in-als-patients-using-radicava 2025-01-29T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/feb00c1a971c0422/fda-fast-track-status-granted-to-vicore-s-novel-ipf-drug-buloxibutid 2025-01-29T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/69e4673eb4d13b0c/minnesota-oncology-leverages-value-based-care-experience-in-eom-transition 2025-01-29T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/c29f7168d0cc4ab1/tme-pharma-partners-with-aimed-analytics-to-advance-ai-driven-cancer-drug-development 2025-01-29T07:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ed4450e007b698e/teva-reports-strong-q4-2024-results-exceeds-revenue-expectations-with-promising-pipeline-progress 2025-01-29T06:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f140a760f01b598/mizuho-securities-maintains-hold-rating-on-neurocrine-as-osavampator-development-faces-timeline-uncertainties 2025-01-29T06:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/00d9cedfd717ac4f/network-meta-analysis-reveals-comparable-efficacy-among-leading-chronic-constipation-treatments 2025-01-29T05:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/be6522ef47531aa9/mayo-clinic-expert-outlines-strategies-to-balance-cancer-drug-costs-and-supply-chain-stability 2025-01-29T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/843357c9e98e5d89/icmr-launches-large-scale-bcg-vaccine-trial-in-adults-for-tb-control 2025-01-29T04:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/a096870cb23b3be7/ator-1017-shows-promising-safety-profile-and-early-efficacy-in-advanced-cancer-trial-published-in-jitc 2025-01-29T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cd0029892137386c/clinical-trial-data-quality-hinges-on-site-level-management-experts-emphasize-at-oct-medical-devices-2025 2025-01-29T03:55:20+00:00 hourly 0.9 https://trial.medpath.com/news/d0932d3efa6507d9/t-dm1-shows-mixed-results-in-phase-2-trial-for-her2-biliary-tract-cancer 2025-01-29T03:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/6fa24040e5c5c1d6/safety-concerns-mount-as-alzheimer-s-drug-leqembi-linked-to-patient-death 2025-01-29T03:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/6569256cadd22789/australia-approves-syfovre-as-first-treatment-for-geographic-atrophy-offering-hope-to-75000-patients 2025-01-29T03:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/c58eff1140e3317d/europe-s-premier-biomarker-companion-diagnostics-summit-returns-to-london-in-2025 2025-01-29T02:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/f6a6679c88524337/eversana-and-lyfegen-form-strategic-alliance-to-transform-global-drug-pricing-and-access 2025-01-29T02:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/dc998a93164b1673/leap-therapeutics-reports-mixed-phase-ii-results-for-sirexatamab-in-gastrointestinal-cancers 2025-01-29T02:13:28+00:00 hourly 0.9 https://trial.medpath.com/news/c572a361bea4052a/fda-clears-allogene-s-novel-dual-target-car-t-therapy-for-autoimmune-disease-trial 2025-01-29T02:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/79371a60e3d24161/inmune-bio-expands-veterans-access-to-novel-nk-cell-therapy-trial-for-metastatic-prostate-cancer 2025-01-29T02:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/d2aa8db2eadc73de/neurocrine-acquires-global-rights-to-promising-depression-drug-osavampator-from-takeda 2025-01-29T02:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae45d7c2420f4746/sab-142-shows-promising-safety-profile-in-phase-1-trial-for-type-1-diabetes-treatment 2025-01-29T02:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/78f798f361b4fe18/cd39-targeted-therapies-pipeline-expands-over-15-candidates-in-development-with-first-approval-expected-by-2029 2025-01-29T02:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/dff3f1813e269be9/itm-11-achieves-breakthrough-in-phase-3-trial-radiopharmaceutical-outperforms-standard-therapy-for-gep-nets 2025-01-29T02:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/6c81c166362dc450/aha-advisory-evt-shows-promise-in-large-core-stroke-treatment-six-clinical-trials-reveal 2025-01-29T00:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/cbcb493e50939a81/large-scale-online-lifestyle-intervention-shows-promise-in-reducing-cognitive-decline-risk 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/0515f9ca2bce6887/mirage-trial-demonstrates-promise-of-mri-guided-sbrt-in-reducing-prostate-cancer-treatment-toxicity 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/d39201dcebce24e5/avidity-biosciences-secures-345m-following-promising-duchenne-muscular-dystrophy-trial-results 2025-01-29T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/59396faeadb52b63/cleveland-clinic-s-20-year-brain-study-reveals-early-disease-markers-seeks-diverse-participation 2025-01-28T22:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/e1c3af7093a3d460/novel-injectable-hydrogel-shows-promise-in-rapidly-strengthening-osteoporotic-bones 2025-01-28T21:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ac20779d7a66873/fda-approval-of-ritlecitinib-marks-new-era-in-adolescent-alopecia-areata-treatment 2025-01-28T20:20:21+00:00 hourly 0.9 https://trial.medpath.com/news/8c74cd9f5821b4f3/fda-grants-510-k-clearance-to-instylla-s-novel-tembo-embolic-system-for-vascular-embolization 2025-01-28T19:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/124e8d8db71d6946/fda-s-q1-q2-2025-pipeline-eight-critical-infectious-disease-products-under-review 2025-01-28T19:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/94af3bd6e6de5e5d/veru-s-enobosarm-shows-promise-in-muscle-preservation-during-glp-1-weight-loss-despite-market-skepticism 2025-01-28T17:54:19+00:00 hourly 0.9 https://trial.medpath.com/news/1a663f29fabd7c35/oxford-health-launches-groundbreaking-psilocybin-trial-for-treatment-resistant-depression 2025-01-28T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/e9be94500b62bcbc/leap-therapeutics-reports-mixed-results-from-cancer-clinical-trials 2025-01-28T17:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/d7bd4bb8a448b7d1/neurocrine-initiates-phase-3-program-for-novel-depression-drug-osavampator 2025-01-28T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/bee6be5e2fd1231f/cagent-vascular-launches-500-patient-registry-to-evaluate-serranator-r-balloon-technology-for-pad-treatment 2025-01-28T17:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/167b72b55427b811/uic-scientists-develop-safer-asparaginase-treatment-for-pediatric-leukemia 2025-01-28T16:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/ad38bab6c8e878c4/recent-advances-and-therapeutic-applications-of-fgf-based-drug-development 2025-01-28T15:46:16+00:00 hourly 0.9 https://trial.medpath.com/news/e420a3b019a555fd/global-study-reveals-widespread-vitamin-d-and-micronutrient-deficiencies-in-type-2-diabetes-patients 2025-01-28T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/c960e6005ef5bf81/servier-to-present-case-for-novel-idh-mutant-glioma-drug-vorasidenib-at-ema-review 2025-01-28T15:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/1e180bc08006e2df/four-major-fda-decisions-in-urology-expected-by-mid-2025-novel-therapies-for-cancer-and-utis-under-review 2025-01-28T15:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/1ce876a4caa1128c/telotristat-ethyl-shows-promise-in-managing-weight-loss-for-metastatic-pancreatic-cancer-patients 2025-01-28T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f4c4f04c5c8de82c/who-launches-global-platform-to-accelerate-tuberculosis-treatment-trials 2025-01-28T14:49:46+00:00 hourly 0.9 https://trial.medpath.com/news/c6002c4217ebdb91/atalanta-therapeutics-secures-97m-series-b-to-advance-cns-targeted-rnai-therapies 2025-01-28T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/51bca433a2a380c4/fda-expands-enhertu-approval-for-most-common-form-of-breast-cancer 2025-01-28T14:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/75c740973748608a/helicore-biopharma-launches-with-65m-to-develop-novel-gip-targeting-obesity-treatment 2025-01-28T14:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/19ed6688e13a9d96/persephone-biosciences-completes-enrollment-for-landmark-microbiome-diet-study-in-colorectal-cancer-prevention 2025-01-28T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8515db9b4867430b/sirexatamab-shows-promising-35-response-rate-in-second-line-colorectal-cancer-trial 2025-01-28T13:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/444573bc3964a158/telomir-1-shows-complete-reversal-of-oxidative-stress-in-breakthrough-preclinical-study 2025-01-28T13:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/f561938069b5cf4b/trump-administration-s-grant-freeze-imperils-591-billion-in-federal-medicaid-funding 2025-01-28T12:57:16+00:00 hourly 0.9 https://trial.medpath.com/news/093fde5588f21e4d/icecure-seeks-nmpa-approval-for-advanced-prosense-cryoablation-system-in-china 2025-01-28T12:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9b6bbc4eca66c2c/mayo-clinic-launches-groundbreaking-neural-cell-therapy-trial-for-drug-resistant-epilepsy 2025-01-28T12:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/1715a4b4d3465a46/fda-grants-dual-designations-to-seed-s-novel-molecular-glue-for-rare-pediatric-cancers 2025-01-28T12:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/812a6a1b2de6d7fb/gossamer-bio-to-present-seralutinib-data-for-pah-treatment-at-pvri-2025-congress 2025-01-28T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/5c1825a736c1deb3/walden-biosciences-strengthens-board-with-appointment-of-rare-disease-expert-howard-mayer 2025-01-28T12:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/c1a6173204b76be7/leap-therapeutics-halts-gastric-cancer-program-after-phase-2-trial-disappointment 2025-01-28T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3cfd219bede6bc9a/sotrovimab-shows-targeted-efficacy-in-covid-19-patients-with-high-viral-loads-recovery-trial-finds 2025-01-28T11:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/36e769e4dc57aea1/medicare-annual-wellness-visit-program-set-for-major-expansion-in-2025 2025-01-28T11:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/3a78aa43e2c07535/fda-grants-spa-agreement-for-descartes-08-phase-3-trial-in-myasthenia-gravis 2025-01-28T11:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/1cb301884ada11c5/corsair-pharma-adopts-instantgmp-s-digital-platform-to-advance-pah-treatment-development 2025-01-28T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/5fe6fcd21e279fa6/roche-s-dmd-treatment-shows-promising-results-in-clinical-trial 2025-01-28T10:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/671daed751d30499/clinical-trials-should-be-viewed-as-standard-care-option-not-last-resort-experts-emphasize 2025-01-28T10:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/fc7583238ba6b35c/larsucosterol-shows-promising-90-day-mortality-reduction-in-phase-2b-alcohol-associated-hepatitis-trial 2025-01-28T10:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/c134e2a4eb5b5d52/fda-issues-noncompliance-notice-over-clinicaltrials-gov-reporting-failure-signals-stricter-enforcement 2025-01-28T09:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/146297a40a0125f6/grove-ai-revolutionizes-clinical-trial-recruitment-with-ai-agent-grace 2025-01-28T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/ac5cb2a14c848de0/ema-endorses-macustar-s-novel-amd-assessment-methods-in-landmark-clinical-study 2025-01-28T09:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/5db790c47419f923/lanifibranor-shows-promise-in-mash-patients-with-type-2-diabetes-legend-trial-results 2025-01-28T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/79264314c6fc9cfb/oncozenge-secures-sek-30-2m-strategic-investment-for-phase-3-bupizenge-trial 2025-01-28T09:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/7f6a40f0f6115253/novel-bacillus-spore-nasal-spray-shows-promise-in-treating-pediatric-ear-and-sinus-infections 2025-01-28T09:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/e85f93fbe081102b/fda-clears-panopticai-s-iphone-based-contactless-vital-signs-monitoring-app 2025-01-28T09:02:02+00:00 hourly 0.9 https://trial.medpath.com/news/e35b0585395856f6/an2-therapeutics-epetraborole-shows-promise-in-phase-2-ntm-lung-disease-trial 2025-01-28T08:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f4b82f9ce2c2367/fda-accepts-nda-for-novel-bumetanide-nasal-spray-for-edema-treatment 2025-01-28T08:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/048729c2073d4016/digital-trust-crisis-80-of-healthcare-professionals-distrust-pharma-s-digital-content 2025-01-28T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/0077ac8b1ba47d39/5-meo-dmt-nasal-spray-shows-promise-in-phase-2a-alcohol-use-disorder-trial 2025-01-28T06:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4e691bf41a04b04/ema-waives-pediatric-trial-requirements-for-mesdopetam-in-parkinson-s-disease 2025-01-28T06:01:19+00:00 hourly 0.9 https://trial.medpath.com/news/3c0ffcb0d810939d/23andme-launches-discover23-platform-for-secure-access-to-massive-research-cohort-data 2025-01-28T06:00:08+00:00 hourly 0.9 https://trial.medpath.com/news/598d1aa32c5b8a33/quibim-secures-50m-series-a-to-advance-ai-powered-medical-imaging-diagnostics 2025-01-28T05:49:30+00:00 hourly 0.9 https://trial.medpath.com/news/6d19de47ffc78a1e/novel-virus-therapy-shows-promise-in-reducing-basal-cell-carcinoma-before-surgery 2025-01-28T05:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/d8e0163973da6c50/sun-pharma-receives-cdsco-approval-for-phase-iii-semaglutide-trial-with-enhanced-safety-monitoring 2025-01-28T05:31:39+00:00 hourly 0.9 https://trial.medpath.com/news/f322a6df2f3ad3b1/novel-gene-therapy-shows-promise-in-treating-recurrent-respiratory-papillomatosis-with-51-complete-response-rate 2025-01-28T05:01:10+00:00 hourly 0.9 https://trial.medpath.com/news/f354950469e767b9/fruquintinib-tas-102-combination-shows-promising-survival-benefits-in-advanced-colorectal-cancer 2025-01-28T04:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/57baf442cac22e41/pfizer-to-present-landmark-survival-data-for-cancer-therapies-at-asco-gu-2025-symposium 2025-01-28T03:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/60913f96d3bc6400/virtual-reality-emerges-as-potential-solution-to-nhs-surgical-backlog-crisis 2025-01-28T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/529c7217f4ea06a2/veru-s-enobosarm-shows-promise-in-phase-iib-trial-for-enhanced-weight-management 2025-01-28T03:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/8238db5d538ad8be/ema-s-chmp-reviews-novel-cancer-adcs-and-vaccines-in-latest-assessment-round 2025-01-28T03:01:40+00:00 hourly 0.9 https://trial.medpath.com/news/2cd41c8b59704543/gene-therapy-shows-promising-results-in-huntington-s-disease-uniqure-trial-reports-significant-disease-progression-reduction 2025-01-28T03:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/5552535a350ec48f/adcs-reshape-nsclc-treatment-landscape-key-trials-show-promise-and-challenges 2025-01-28T02:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/fad52c27e6814037/oct-west-coast-2025-conference-to-focus-on-trial-efficiency-ai-integration-and-patient-centricity 2025-01-28T01:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/f12d77c25cf74ba6/phase-2-calliper-trial-shows-promise-for-immunic-s-vidoca-in-progressive-multiple-sclerosis 2025-01-28T01:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/caa5c382e4fcd604/tectonic-s-tx45-shows-promise-for-pulmonary-hypertension-treatment-receives-analyst-upgrade 2025-01-28T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/06246da47d368b38/long-term-study-shows-sustained-benefits-of-nt-501-cell-therapy-for-macular-telangiectasia-type-2 2025-01-28T01:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/66dd546f02799523/oncomatryx-secures-eur25m-funding-to-advance-novel-cancer-microenvironment-targeting-adc-trials 2025-01-28T01:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/0838a802251c2b93/allakos-cuts-75-of-workforce-following-failed-urticaria-drug-trial 2025-01-28T00:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/cf922bd2ca36b42c/np001-shows-22-month-survival-benefit-in-select-als-patients-new-trial-analysis-reveals 2025-01-28T00:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/70ba308f10ed49b7/phase-2-trial-shows-baricitinib-plus-uv-therapy-achieves-45-improvement-in-severe-vitiligo 2025-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe52387ce38d3d35/novel-hmb-supplement-trial-launches-to-combat-cirrhosis-symptoms-in-ps500000-uk-study 2025-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/49b31ca4db386d80/altimmune-halts-nasal-covid-19-vaccine-development-after-poor-phase-1-results 2025-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6d53e74b3242fc44/fda-aligns-with-gemini-therapeutics-on-apollo-trial-design-for-bitopertin-in-rare-porphyria-disorders 2025-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/67d5633f5c6067c7/novavax-launches-phase-1-2-trial-of-nanoparticle-based-covid-19-vaccine-with-384m-cepi-backing 2025-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/74275402146a18b9/johns-hopkins-launches-clinical-trial-to-evaluate-tetracycline-for-post-lyme-disease-symptoms 2025-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e126a34d160a0571/fda-greenlights-amgen-and-allergan-s-herceptin-biosimilar-kanjinti-amid-patent-expiry 2025-01-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/91b4dd45eeeef28f/dutch-court-upholds-astellas-xtandi-formulation-patent-against-synthon-challenge 2025-01-27T23:57:35+00:00 hourly 0.9 https://trial.medpath.com/news/9166535621e01df1/immusoft-reports-breakthrough-first-engineered-b-cell-therapy-shows-promise-in-mps-i-clinical-trial 2025-01-27T23:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/84708331e9e7e874/alterity-therapeutics-halts-trading-ahead-of-critical-phase-ii-neurodegenerative-disease-trial-results 2025-01-27T23:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/8b7857aa467ec809/coya-therapeutics-advances-novel-treg-based-als-treatment-with-phase-2b-trial-planned-for-2025 2025-01-27T23:01:35+00:00 hourly 0.9 https://trial.medpath.com/news/75a7f75c8d0c305a/nih-backed-taichiknee-trial-investigates-web-based-tai-chi-for-knee-osteoarthritis-treatment 2025-01-27T23:01:09+00:00 hourly 0.9 https://trial.medpath.com/news/68f33c9660ed9216/blood-protein-signature-identified-in-pediatric-long-covid-opening-path-for-diagnostic-test 2025-01-27T22:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/99380485aed9ce9f/first-patient-dosed-in-phase-2-trial-of-triplex-cmv-vaccine-for-stem-cell-transplant-donors 2025-01-27T22:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/77133d47beb3f1cd/theralase-s-light-activated-bladder-cancer-therapy-shows-promising-results-in-phase-ii-trial 2025-01-27T22:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b975df2cdd5e54b/ema-approves-phase-2-trial-of-novel-melas-treatment-tti-0102 2025-01-27T21:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/b04d9a1491140867/ramucirumab-plus-somatostatin-shows-promise-in-advanced-neuroendocrine-tumors-with-14-2-month-pfs 2025-01-27T21:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/eba3c0fd6fbeeb5a/early-detection-of-mixed-chimerism-predicts-leukemia-relapse-risk-in-aml-transplant-patients 2025-01-27T21:01:30+00:00 hourly 0.9 https://trial.medpath.com/news/3866d2ec092119d1/arfolitixorin-shows-promise-in-post-hoc-analysis-of-phase-iii-agent-trial-for-colorectal-cancer 2025-01-27T21:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/9f831ac6709e596b/breakthrough-brain-infusion-therapy-shows-promise-in-advanced-parkinson-s-disease-treatment 2025-01-27T20:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/42986a1e6d9466ec/achieve-life-sciences-nears-fda-filing-for-novel-smoking-cessation-drug-following-successful-trials 2025-01-27T20:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/d3b6feb7abf2cfc2/sana-biotechnology-achieves-breakthrough-in-type-1-diabetes-treatment-without-immunosuppression 2025-01-27T20:01:21+00:00 hourly 0.9 https://trial.medpath.com/news/ea93051babe174b1/fda-clears-imperative-care-s-zoom-system-with-novel-large-bore-catheter-for-stroke-treatment 2025-01-27T19:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/6bba952e91ab5bc7/fda-updates-viloxazine-label-with-new-pharmacodynamic-data-for-adhd-treatment 2025-01-27T19:31:14+00:00 hourly 0.9 https://trial.medpath.com/news/d91661b389930edf/fda-approves-monthly-maintenance-dosing-for-leqembi-in-early-alzheimer-s-treatment 2025-01-27T19:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/aa454a9754304377/veru-s-enobosarm-shows-promise-in-preserving-muscle-mass-during-wegovy-treatment 2025-01-27T19:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/d54d8f4868d96437/new-study-shows-ulipristal-misoprostol-combination-achieves-97-success-rate-for-medical-abortion 2025-01-27T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/3180832993244637/phase-3-trial-shows-oral-liporaxel-extends-survival-in-advanced-gastric-cancer-compared-to-iv-formulation 2025-01-27T16:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/db87b6f2c1fcd214/eu-launches-eur9-5m-path4young-initiative-to-revolutionize-breast-cancer-care-for-young-women 2025-01-27T15:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/4ff649e27a9f6115/efruxifermin-glp-1ra-combination-shows-promise-in-mash-treatment-study 2025-01-27T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/abb8be835dc15d76/hvivo-and-iliad-launch-groundbreaking-phase-3-human-challenge-trial-for-whooping-cough-vaccine 2025-01-27T14:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/547aadc7085c8a17/cerebrolysin-shows-promise-in-improving-outcomes-after-mechanical-thrombectomy-for-acute-stroke 2025-01-27T14:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/005da973c75d15f9/london-clinic-becomes-first-in-europe-to-offer-both-novel-alzheimer-s-drugs-privately 2025-01-27T14:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/f5ee952aca84d41e/iovance-biotherapeutics-advances-melanoma-treatment-portfolio-with-amtagvi-launch-and-pipeline-expansion 2025-01-27T13:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/d0b710860f4375ed/insmed-s-tpip-and-brensocatib-programs-show-promise-in-rare-pulmonary-diseases 2025-01-27T13:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/5b90c4258faa8c39/meta-analysis-reveals-comparable-efficacy-between-ect-and-ketamine-for-treatment-resistant-depression 2025-01-27T13:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/f2004a3daed8a178/tisento-therapeutics-initiates-global-phase-2b-trial-of-zagociguat-for-melas-treatment 2025-01-27T13:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/4168bbe78ee7006b/fda-clears-ocugen-s-ind-for-novel-inhaled-covid-19-vaccine-ocu500-phase-1-trial-set-for-q2-2025 2025-01-27T13:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/63e2e09f55b2b287/enobosarm-shows-promise-in-preserving-muscle-mass-during-glp-1-weight-loss-treatment 2025-01-27T13:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/45d96072f82e8205/abbvie-s-immunology-portfolio-shows-strong-growth-potential-despite-emraclidine-setback 2025-01-27T13:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ffa71b6ca4d584c/oxford-and-gsk-launch-ps50m-cancer-prevention-vaccine-research-program 2025-01-27T12:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/f043dbc8435b0c9a/exelixis-shows-promise-in-metastatic-colorectal-cancer-treatment-with-zanzalintinib-combination-therapy 2025-01-27T12:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/0f4cfab3ef58d559/extended-release-glaucoma-treatments-face-cost-barriers-despite-innovation-in-drug-delivery 2025-01-27T11:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ee8df67213a023c/ab2-bio-and-nippon-shinyaku-strike-686m-deal-for-rare-disease-drug-tadekinig-alfa 2025-01-27T11:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/f3797d54024c7f30/bicara-s-ficerafusp-alfa-shows-promise-in-egfr-anal-cancer-trial-when-combined-with-keytruda 2025-01-27T11:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a86ae79ef079c39/historical-redlining-linked-to-higher-cancer-mortality-risk-in-young-patients-study-reveals 2025-01-27T11:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/7727f5a9a612ec19/fda-issues-draft-guidance-on-ich-e6-r3-implementation-focus-on-decentralized-trials-and-real-world-data 2025-01-27T10:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/af59ae461820699e/agenus-reports-promising-survival-data-for-bot-bal-combination-in-colorectal-cancer-treatment 2025-01-27T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/df78c27d89a9506e/novel-platelet-therapy-shows-promise-in-treating-covid-19-related-smell-loss 2025-01-27T08:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/09bbd647fd36d616/innate-pharma-initiates-phase-1-trial-of-novel-nectin-4-adc-for-advanced-solid-tumors 2025-01-27T07:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/c6a5b889305b7230/bicara-s-ficerafusp-alfa-shows-promise-in-advanced-anal-cancer-trial 2025-01-27T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/e2f32f4cf4c06ed4/ai-reshaping-drug-discovery-nobel-winning-alphafold-leads-revolution-in-pharmaceutical-r-d 2025-01-27T06:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/54e0ec9a8c2465bf/gt-biopharma-initiates-phase-1-trial-of-novel-trike-therapy-gtb-3650-for-blood-cancers 2025-01-27T06:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/cdc41caad16ef410/adagene-s-adg126-keytruda-combination-shows-promising-33-response-rate-in-mss-colorectal-cancer-trial 2025-01-27T06:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/f07a18c0a8b8815a/oncopeptides-secures-italian-reimbursement-for-multiple-myeloma-drug-pepaxti 2025-01-27T05:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/0598cb692aa8964d/strategic-intelligence-solutions-reshape-pharmaceutical-industry-decision-making 2025-01-27T04:59:34+00:00 hourly 0.9 https://trial.medpath.com/news/8365260f4dacddbf/kailera-therapeutics-strengthens-commercial-leadership-with-ex-lilly-executive-jamie-coleman-ahead-of-phase-3-obesity-drug-program 2025-01-27T04:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/30a571dfa9cf9563/enhanced-recovery-protocol-reduces-hospital-stay-for-elderly-patients-undergoing-pelvic-floor-surgery 2025-01-27T04:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/abc41699e5c11fb8/akeso-s-novel-il-17-inhibitor-gumokimab-shows-promising-results-for-psoriasis-treatment-in-phase-iii-trial 2025-01-27T04:31:02+00:00 hourly 0.9 https://trial.medpath.com/news/71e6ff19fb9428e2/amgen-launches-1-5b-manufacturing-hub-in-north-carolina-with-advanced-sustainable-technology 2025-01-27T00:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/50cc81fa0caded6d/cihr-implements-mandatory-clinical-trial-registration-and-results-disclosure-policy 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/408afc36618a79b5/bariatric-surgery-slashes-liver-complication-risks-by-72-in-obese-cirrhosis-patients 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ff4d4edabe6e14c9/nourish-trial-addresses-food-insecurity-and-malnutrition-in-blood-cancer-patients-during-treatment 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/97c37e0b8ccb2f6c/alnylam-s-novel-rnai-hypertension-drug-zilebesiran-receives-mhra-innovation-passport 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d33da5f1be3fbc5c/fda-expands-evrysdi-approval-to-include-infants-under-two-months-with-spinal-muscular-atrophy 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/45e7e1682249bce7/meta-analysis-reveals-31-of-weight-loss-from-glp-1-therapy-attributed-to-lean-mass-reduction 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bdf2c60a027819af/phase-3-trial-shows-successful-switch-from-ustekinumab-to-biosimilar-sb17-in-psoriasis-treatment 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/52a486a8645dcf02/ventyx-reports-promising-52-week-data-for-tamuzimod-in-ulcerative-colitis-treatment 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a391c24b9536f7f/fda-clears-northwestern-university-s-ind-application-for-calidi-s-novel-glioma-treatment-cld-101 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bb14de1990dbeecb/novartis-launches-phase-2-trial-of-car-t-cell-therapy-for-lupus-nephritis 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/14cd61e54234f922/fda-issues-partial-clinical-hold-on-gilead-s-magrolimab-azacitidine-combination-trials 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c663d20dd91d0454/herantis-pharma-advances-her-096-in-phase-1b-trial-for-parkinson-s-disease-with-promising-pharmacokinetic-data 2025-01-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6fc1ef10897c57a6/retail-pharmacies-emerge-as-critical-partners-in-advancing-drug-development-and-patient-care 2025-01-26T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7caac854195690f1/novel-blood-thinner-abelacimab-shows-superior-safety-profile-in-atrial-fibrillation-trial 2025-01-26T19:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/d7657dfca28c4697/wvu-cancer-institute-pioneers-novel-bite-therapy-for-advanced-small-cell-lung-cancer 2025-01-26T16:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/2e5525f75bcc60ec/phase-3-peak-trial-shows-promise-bezuclastinib-sunitinib-combination-demonstrates-improved-outcomes-in-gist-patients 2025-01-26T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/ddc2b4b08ff027dc/hinge-bio-secures-30m-series-a-to-advance-novel-autoimmune-disease-therapy 2025-01-26T07:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/a4b574b61670c6c5/health-experts-warn-of-long-term-risks-from-wildfire-smoke-exposure-emphasize-protection-measures 2025-01-26T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5099a0a07844d9c9/first-reported-case-of-concurrent-hidradenitis-suppurativa-and-porokeratosis-reveals-treatment-challenges 2025-01-26T05:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/12b2db506b199d18/cabozantinib-shows-50-pfs-improvement-in-gi-neuroendocrine-tumors-cabinet-trial-results 2025-01-26T04:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/cd36670105f4d44e/phase-2-trial-launches-to-evaluate-abbv-400-combination-therapy-in-metastatic-colorectal-cancer 2025-01-26T04:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/cd057fb643bc08a3/zanzalintinib-atezolizumab-combination-shows-promise-in-advanced-colorectal-cancer-trial 2025-01-26T04:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/7c8c88a01a613f4c/novel-immunomodulation-therapies-show-promise-in-cerebral-palsy-prevention-research 2025-01-26T04:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/69e043184f318203/chinese-bci-breakthrough-epilepsy-patient-successfully-controls-speech-and-movement-through-brain-computer-interface 2025-01-26T04:31:29+00:00 hourly 0.9 https://trial.medpath.com/news/1ba11c85cf1d070b/watch-and-wait-approach-proves-safe-alternative-to-surgery-in-responsive-rectal-cancer-patients 2025-01-26T04:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/baccf96e59ca88f2/geriatric-assessment-and-quality-of-life-metrics-predict-survival-outcomes-in-elderly-pancreatic-cancer-patients 2025-01-26T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/4d37d35056e85f20/novel-fmt-strategy-shows-promise-in-preventing-severe-graft-versus-host-disease-after-stem-cell-transplantation 2025-01-26T01:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/587b132b03e69fc1/anthracyclines-show-promise-in-treating-rare-genetic-skin-disorder-by-restoring-mutant-p63-function 2025-01-26T01:31:31+00:00 hourly 0.9 https://trial.medpath.com/news/f5114d73a892b870/pelareorep-folfirinox-combination-shows-promising-safety-profile-in-metastatic-pancreatic-cancer-trial 2025-01-26T01:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/7c962c311c5732cf/cardiac-surgeons-call-for-greater-role-as-transcatheter-tricuspid-valve-treatments-advance 2025-01-26T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/481d1f774c7ab3fe/pfizer-biontech-seeks-fda-authorization-for-bivalent-covid-19-vaccine-in-children-under-5 2025-01-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd4f27341efb6ff8/msd-discontinues-development-of-tigit-and-lag-3-cancer-immunotherapy-programs 2025-01-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/e4fed63c9335756a/who-led-clinical-trials-validate-outpatient-treatment-for-infant-bacterial-infections-in-low-resource-settings 2025-01-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a2a2b21bb6ba3c7a/novel-car-t-cell-therapy-gcc19cart-shows-promising-results-in-metastatic-colorectal-cancer-trial 2025-01-25T22:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/785eafcea8baf810/cabozantinib-shows-significant-pfs-benefit-in-gi-origin-neuroendocrine-tumors-phase-3-cabinet-trial-results 2025-01-25T22:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/404ee25807b16660/trifluridine-tipiracil-shows-significant-dfs-improvement-in-resected-stage-iv-colorectal-cancer-patients 2025-01-25T22:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/e0a66249d9bce68b/novel-cadonilimab-chemo-combo-achieves-37-complete-response-in-advanced-rectal-cancer-trial 2025-01-25T22:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/6a73aab142b79df0/single-dose-of-keytruda-before-surgery-shows-promise-in-early-stage-dmmr-colon-cancer 2025-01-25T22:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/247bbc9037551fc4/nalirifox-shows-promising-survival-advantage-over-folfirinox-in-metastatic-pancreatic-cancer-real-world-analysis 2025-01-25T22:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/bb1c3c5c8c0ee3d6/bevacizumab-benefits-in-colorectal-cancer-limited-to-two-year-window-new-analysis-reveals 2025-01-25T22:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/792001ca47f91629/astrazeneca-plans-major-clinical-trial-expansion-in-philippines 2025-01-25T22:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/4047d97eb691fdae/stanford-study-cancer-drug-ebc-46-shows-breakthrough-potential-for-hiv-eradication 2025-01-25T22:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/8f1803d2a43db196/bristol-myers-opdivo-yervoy-combination-shows-38-reduction-in-colorectal-cancer-relapse-risk 2025-01-25T20:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/97d875d4fa88f0dd/novel-peptide-certepetide-shows-mixed-results-when-added-to-standard-pancreatic-cancer-treatment 2025-01-25T19:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/b6b6d81c3425d98a/aspirin-reduces-cancer-recurrence-by-over-50-in-pi3k-mutated-colorectal-cancer-alascca-trial-shows 2025-01-25T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/1678692f62e2d3aa/dose-reductions-in-nalirifox-regimen-show-no-negative-impact-on-pancreatic-cancer-survival 2025-01-25T19:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/efd2704ea7825808/biosimilars-prove-safe-and-effective-for-pediatric-ibd-treatment-in-large-french-study 2025-01-25T19:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/aab82cf385c780bc/opdivo-yervoy-combination-shows-superior-survival-benefits-in-advanced-liver-cancer-trial 2025-01-25T17:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/6b5958e79a9869fb/lixumistat-shows-promising-results-in-phase-1b-pancreatic-cancer-trial 2025-01-25T17:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/63541688d4ade05c/novo-nordisk-s-amycretin-shows-22-weight-loss-in-phase-1b-2a-obesity-trial 2025-01-25T16:03:27+00:00 hourly 0.9 https://trial.medpath.com/news/3b9fe3fcc275efc4/anavex-s-blarcamesine-shows-promising-results-in-alzheimer-s-disease-maa-submission-advances-eu-strategy 2025-01-25T16:03:12+00:00 hourly 0.9 https://trial.medpath.com/news/3151acfd31250a5f/phase-3-lapis-trial-pamrevlumab-chemotherapy-combination-shows-no-survival-benefit-in-advanced-pancreatic-cancer 2025-01-25T16:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/9ebf93029eabdb33/zoldonrasib-shows-promising-safety-and-efficacy-in-kras-g12d-mutated-pancreatic-cancer-trial 2025-01-25T16:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/f7a901d36402ba2c/novel-oral-rdrp-inhibitor-shen26-shows-promise-in-phase-ii-covid-19-trial 2025-01-25T16:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/2e42f41cb0010069/ctdna-status-predicts-celecoxib-benefit-in-stage-iii-colon-cancer-phase-3-trial-shows 2025-01-25T16:02:05+00:00 hourly 0.9 https://trial.medpath.com/news/0bcbb855725394e6/novel-low-dose-copper-iud-shows-promise-in-phase-3-trial-with-99-efficacy-rate 2025-01-25T16:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/782e9100f265226f/phase-3-accelerate-trial-chemoradiation-addition-shows-no-rfs-benefit-in-resected-gallbladder-cancer 2025-01-25T16:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/2c15741915e86b90/pantheon-vision-advances-development-of-bioengineered-corneal-implants-following-fda-meeting 2025-01-25T15:52:38+00:00 hourly 0.9 https://trial.medpath.com/news/23d67e99f66a9e25/ascentage-pharma-secures-126m-in-first-us-biotech-ipo-of-2025-advancing-novel-cancer-therapies 2025-01-25T15:52:20+00:00 hourly 0.9 https://trial.medpath.com/news/48ff776a392c5e45/faricimab-rechallenge-linked-to-severe-vision-loss-in-patients-with-prior-inflammation 2025-01-25T15:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/4811401eb0d9cb75/blood-test-predicts-celecoxib-s-effectiveness-in-preventing-colon-cancer-recurrence 2025-01-25T15:51:44+00:00 hourly 0.9 https://trial.medpath.com/news/518b5adce3efa271/digoxin-shows-promise-in-disrupting-cancer-cell-clusters-opening-new-path-for-metastasis-prevention 2025-01-25T15:51:30+00:00 hourly 0.9 https://trial.medpath.com/news/baf50162d411f237/novel-biotherapeutic-ve303-shows-80-reduction-in-recurrent-c-difficile-infection-risk 2025-01-25T15:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/23e3d062a2fc7043/checkpoint-inhibitor-use-surges-following-fda-approval-for-gastroesophageal-cancer-treatment 2025-01-25T15:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/da80cf85faa710d7/reithera-and-sillajen-partner-to-advance-novel-anticancer-virus-platform-for-clinical-development 2025-01-25T15:50:41+00:00 hourly 0.9 https://trial.medpath.com/news/3c3b41c7a2fc889f/merck-and-eisai-s-keytruda-lenvima-combo-shows-mixed-phase-3-results-in-gastric-cancer 2025-01-25T15:50:29+00:00 hourly 0.9 https://trial.medpath.com/news/8652e5f9982dd619/real-world-study-shows-palliative-care-benefits-young-colorectal-cancer-patients-at-end-of-life 2025-01-25T13:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/ae95e5600799af46/attovia-therapeutics-initiates-phase-1-trial-of-novel-anti-il-31-therapy-for-chronic-pruritus 2025-01-25T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4248f3d182023278/gender-based-study-reveals-distinct-ptsd-symptom-patterns-in-early-trauma-response 2025-01-25T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/98cc5d84a704c9a7/radiotherapy-shows-survival-benefits-for-elderly-patients-with-early-stage-triple-negative-breast-cancer 2025-01-25T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1c0535ef39c3e7a1/study-finds-no-direct-causal-link-between-osteoarthritis-and-cognitive-decline-depression-may-play-key-role 2025-01-25T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b875798114d5f61c/amrita-school-of-ayurveda-study-shows-promise-of-cannabis-based-treatment-for-menstrual-pain 2025-01-25T02:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/77100cd05e2d83d8/flash-radiotherapy-ultra-fast-cancer-treatment-shows-promise-as-radiation-alternative 2025-01-25T00:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e87bc1c47eb5b18/trinity-biotech-reports-breakthrough-in-next-generation-cgm-technology-with-promising-pre-pivotal-trial-results 2025-01-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4f192fdb70c7ef12/roche-s-actemra-shows-promise-in-reducing-covid-19-ventilation-risk-among-minority-patients 2025-01-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3430032db5e53bf7/musc-launches-clinical-trial-for-revolutionary-wire-free-cochlear-implant-system 2025-01-24T23:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/ca182968afcd4247/lonsurf-plus-bevacizumab-shows-improved-survival-in-real-world-metastatic-colorectal-cancer-study 2025-01-24T22:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/7cafa1f72a9f7e2d/fda-removes-clinical-trial-diversity-guidelines-amid-policy-shift 2025-01-24T22:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/6e599cebcb11f90e/tiziana-life-sciences-halts-capital-raising-plans-following-positive-ms-biomarker-discovery 2025-01-24T19:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/6fb11c6729d62804/perspective-therapeutics-reports-positive-safety-and-early-efficacy-data-in-net-cancer-trial 2025-01-24T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/156137321e3be71d/reduced-dexamethasone-dosing-shows-comparable-survival-outcomes-in-multiple-myeloma-treatment 2025-01-24T16:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/70553417b580427f/phase-1-2-keymaker-u02-trial-pembrolizumab-shows-manageable-safety-profile-in-stage-iiib-d-melanoma 2025-01-24T16:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/fca8a8cdecf27092/novel-blood-test-shows-79-sensitivity-in-colorectal-cancer-detection-preempt-crc-trial-reports 2025-01-24T15:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/cf4eade31de49760/alterity-s-ath434-phase-2-trial-in-early-stage-msa-completes-with-results-expected-february-2025 2025-01-24T15:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/5531fb7398f8bc70/unc-researchers-lead-groundbreaking-hiv-clinical-trials-in-vietnam 2025-01-24T14:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/123c3131c78b4ed4/ema-validates-marketing-authorization-application-for-mavorixafor-in-whim-syndrome-treatment 2025-01-24T14:01:06+00:00 hourly 0.9 https://trial.medpath.com/news/544c3e4fc1122b5d/china-medical-system-s-mg-k10-advances-in-phase-iii-trials-for-multiple-inflammatory-conditions 2025-01-24T14:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/1000f1cfb3eca1cd/novo-nordisk-s-novel-amycretin-shows-22-weight-reduction-in-early-stage-trial 2025-01-24T13:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/f5addd2357d3609c/novel-hydrogel-based-immunotherapy-shows-promise-in-triple-negative-breast-cancer-treatment 2025-01-24T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/92723a2375ab1887/prophylactic-cardiac-treatment-shows-54-lower-mortality-risk-in-duchenne-muscular-dystrophy-patients 2025-01-24T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/04b71407c6cf9ef8/lenacapavir-shows-promising-results-in-phase-3-trial-for-multidrug-resistant-hiv-1 2025-01-24T11:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/073ecb961b2c657d/new-research-reveals-five-key-mechanisms-linking-alcohol-consumption-to-cancer-development 2025-01-24T11:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/d86cb50d2b109044/onconic-s-jaqbo-shows-100-efficacy-in-phase-3-gastric-ulcer-trial-seeks-expanded-indication 2025-01-24T11:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/87a1988293d742a8/dogwood-therapeutics-novel-pain-drug-halneuron-r-drives-368-stock-rally-amid-phase-2b-trial-launch 2025-01-24T11:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/87b31b5ae1f2c657/prehabilitation-before-surgery-significantly-reduces-complications-and-hospital-stays-study-shows 2025-01-24T11:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/38a7c77a9ca6c027/vigil-neuroscience-reports-promising-early-stage-data-for-novel-alzheimer-s-drug 2025-01-24T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/7e716f404fef6311/first-full-spectrum-cannabis-based-drug-for-autism-enters-clinical-trials-with-promising-phase-1-results 2025-01-24T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9b5de28d3894b36/fda-approves-evatm-first-automated-programming-platform-for-spinal-cord-stimulation 2025-01-24T10:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/b11c94c3a6249e8a/novel-therapeutic-hpv-vaccine-shows-promise-in-eliminating-precancerous-cervical-lesions 2025-01-24T10:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/8387c19e5d49a90b/st-jude-s-narrative-medicine-program-reveals-impact-of-long-acting-hiv-treatments-through-patient-stories 2025-01-24T09:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/9006a52f0ff9a6c1/meta-analysis-confirms-zero-hiv-transmission-risk-in-art-treated-couples 2025-01-24T09:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/acdd9c82638fffd3/pbm-reform-bill-shows-strong-promise-for-2024-passage-aims-to-boost-drug-pricing-transparency 2025-01-24T09:01:36+00:00 hourly 0.9 https://trial.medpath.com/news/0a19c30a1d15cf79/novel-non-invasive-biomarkers-essential-for-advancing-pancreatic-cancer-diagnostics-expert-emphasizes 2025-01-24T08:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/3148acbb52fd8807/aardvark-therapeutics-files-for-100m-ipo-to-advance-novel-hyperphagia-treatment 2025-01-24T08:47:20+00:00 hourly 0.9 https://trial.medpath.com/news/a57c7848ae5f81aa/larimar-therapeutics-advances-pediatric-study-of-nomlabofusp-for-friedreich-s-ataxia 2025-01-24T08:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/050a37cc632393c7/five-key-trends-reshaping-pharmacy-benefits-landscape-in-2025-biosimilars-glp-1s-lead-market-evolution 2025-01-24T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/286dc7530ad4059b/basal-cell-carcinoma-market-set-to-reach-9-7-billion-by-2035-driven-by-early-detection-and-novel-therapies 2025-01-24T07:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/2c776cd17ea0c76a/pharmacists-emerge-as-critical-partners-in-multiple-sclerosis-b-cell-therapy-management 2025-01-24T07:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/5ec0aaa3a75aaa59/deep-response-to-tislelizumab-chemotherapy-combination-correlates-with-extended-survival-in-advanced-esophageal-cancer 2025-01-24T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/180013b4ce0f3de5/medtronic-s-inceptiv-closed-loop-scs-shows-strong-12-month-pain-relief-data 2025-01-24T07:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/3515622e1d294c27/fda-issues-warning-to-sanofi-for-manufacturing-violations-places-clinical-hold-on-atara-s-immunotherapies 2025-01-24T07:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/c6832604682a8001/pain-neuroscience-education-shows-promise-in-reducing-post-operative-pain-after-laparoscopic-hernia-repair 2025-01-24T07:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/fea80222c7985975/aap-implantate-ag-achieves-6-sales-growth-in-2024-reports-progress-in-antibacterial-implants-study 2025-01-24T07:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/d82b2d4b16e24b11/allergan-aesthetics-launches-aa-signature-program-to-transform-personalized-aesthetic-treatments 2025-01-24T06:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/880de9fce2ce40aa/high-out-of-pocket-costs-linked-to-lower-cardiac-rehabilitation-adherence-study-finds 2025-01-24T06:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/a1491f2d3ea69e1b/rakuten-medical-initiates-global-phase-iii-trial-for-head-and-neck-cancer-treatment 2025-01-24T04:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/df2eb58a2ebda0e7/novel-shr-1701-combination-therapy-shows-promise-in-reducing-chemotherapy-induced-myelosuppression-for-gastric-cancer-patients 2025-01-24T04:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/511f4ab7c88ace65/fda-grants-clia-waiver-for-roche-s-rapid-sti-testing-panels-enabling-20-minute-results 2025-01-24T04:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/1e1261f4c1f2eda0/pfa-technology-dominates-cardiac-rhythm-innovation-in-2024-multiple-companies-achieve-key-milestones 2025-01-24T04:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/4675c0ee775c266f/combination-of-afinitor-and-somatuline-shows-superior-results-in-advanced-gep-net-treatment 2025-01-24T04:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/79046d8a2246583d/repatha-safety-data-limited-for-pregnancy-and-breastfeeding-manufacturer-launches-pregnancy-registry 2025-01-24T04:31:07+00:00 hourly 0.9 https://trial.medpath.com/news/525b471f157b28be/biopharma-industry-faces-pivotal-year-j-p-morgan-conference-signals-key-2025-challenges 2025-01-24T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/310804060b37969d/oximio-expands-ultra-cold-storage-capabilities-amid-growing-clinical-trial-logistics-challenges 2025-01-24T03:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/da4f4cc772fafe54/astrazeneca-commits-570m-investment-to-expand-canadian-operations-and-r-d-hub 2025-01-24T03:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/f683d86de2f4b6eb/promising-results-for-her2-targeted-therapy-in-previously-treated-breast-cancer-patients 2025-01-24T02:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/5618bea1b8275b84/5-year-data-confirms-long-term-survival-benefit-of-nivolumab-chemotherapy-combination-in-advanced-gastric-cancers 2025-01-24T01:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/bfd2dd0fca33f75d/rakuten-medical-launches-global-phase-3-trial-combining-photoimmunotherapy-with-pembrolizumab-for-head-and-neck-cancer 2025-01-24T01:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/ba28e29d904b4109/real-world-study-reveals-growing-adoption-of-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma-treatment 2025-01-24T01:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/33d13c4c03b69109/sglt-2-inhibitor-plus-calorie-restriction-doubles-diabetes-remission-success-in-clinical-trial 2025-01-24T01:32:01+00:00 hourly 0.9